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METHODS FOR DIAGNOSING AND 
TREATING ALZHEIMER'S DISEASE (AD) 
USING THE MOLECULES THAT STABILIZE 
INTRACELLULAR CALCIUM (CA2J 
RELEASE 
RELATED APPLICATIONS 
2 
Currently, the major pathological factors known to be 
involved in Alzheimer's Disease (AD) include beta amyloid 
accnmulation, neurofibrillary tangles (NFTs) and synaptic 
dysfunction or loss. In addition, AD is associated with other 
pathological processes, including failing mitochondrial 
function and oxidative stress, increased inflammatory 
response, protein misfolding, altered growth factor signal-
ing, aberrant reentry of neurons into the cell cycle, lyso-
somal activation, endocrine alteration, insulin resistance, This application claims priority to U.S. Provisional Patent 
Application No. 61/533,056, filed Sep. 9, 2011, the entire 
content of which is hereby incorporated herein by reference 
as though fully set forth here. 
10 cholesterol dyshomeostasis, and calcium dysregulation. 
GOVERNMENT LICENSE RIGHTS 
The complexity and number of changes associated with 
AD has impeded attempts to disentangle the processes 
important for pathogenesis and discover a treatment of AD. 
Therefore, there sill remains a need for identifYing agents or 
15 molecules that can be used for diagnosis and/or treating AD. 
SUMMARY 
The subject technology was made with government sup-
port under grants AG034605, AG004542 and AG010836 
awarded by National Institute on Aging. The Government 
may have certain rights to this invention. The subject technology is illustrated, for example, accord-
20 ing to various aspects described below. 
SEQUENCE LISTING In some embodiments, the subject technology relates to a 
method of treating Alzheimer's Disease (AD), early-stage 
AD, elevated risk of AD, mild cognitive impairment (MCI), 
or other forms of age-related cognitive decline in a subject 
The instant application contains a Sequence Listing which 
has been submitted in ASCII format via EFS-Web and is 
hereby incorporated by reference in its entirety. Said ASCII 
copy, created on Dec. 27, 2012, is named Sequence Listing 
50229-0611.txt and is 1,121 bytes in size. 
FIELD 
25 in need thereof. This method includes administering to the 
subject a molecule or combination of molecules that pro-
mote calcium-release stabilization in ryanodine receptors 
(RyR) and/or inosital triphosphate receptors (InsP3R) in the 
brain cells of the subject. In certain embodiments, the 
The subject technology relates to methods and composi-
tions for treating Alzheimer's disease (AD) or other cogni-
tive disorders; it also relates to a method of diagnosing 
individuals who are at risk of developing AD. More spe-
cifically, the subject technology relates to calcium release-
stabilizing molecules that can reduce, inhibit or reverse 
calcinm dysregulation in brain cells. 
30 molecule is a polypeptide, polynucleotide, small molecule or 
large molecule. In an embodiment, the molecule is a poly-
peptide selected from immunophilins, junctophilins or 
calmodulins. In another embodiment, the polypeptide mol-
ecule is FKBP1a, FKBP1b, junctophilin 3, junctophilin 4, 
BACKGROUND 
35 calmodulin 3, a functional fragment thereof or combinations 
thereof. In another embodiment, the molecule is a poly-
nucleotide encoding a polypeptide selected from immuno-
philins, junctophilins or calmodulins. In another embodi-
ment, the polynucleotide molecule is a nucleic acid 
40 sequence encoding at least one of FKBP1a, FKBP1b, junc-
tophilin 3, junctophilin 4, calmodulin 3, a functional frag-
ment thereof or combinations thereof. In some embodi-
ments, the molecule is administered orally, ophthalmically, 
nasally, urogentially, rectally, dermally, or by way of injec-
The characteristic neuropathological and molecular 
lesions that correlate with dementia in Alzheimer's Disease 
(AD) include the accumulation of hyper-phosphorylated and 
poly-ubiquinated microtubule-associated proteins, such as 
tau, resulting in the formation of neurofibrillary tangles, 
dystrophic neuritis, and neuropil threads. Neuronal cytoskel-
etal abnormalities are associated with cerebral atrophy with 
cell and fiber loss, and synaptic disconnection. Increased 
amyloid-beta (A~) deposition around and within the walls of 
meningeal and cortical vessels, the cortical neuropil, and 50 
neuronal perikarya is a feature of both AD and normal aging. 
Although genetic factors can predispose individuals to 
develop premature and excessive cerebral deposits of A~ in 
AD-type dementia, most cases are sporadic and do not 
exhibit clear familial or genetic clustering. Recent explora- 55 
tion of biochemical, molecular, and cellular abnormalities 
that precede or accompany classic AD demonstrated that cell 
loss was associated with increased activation of pro-death 
genes and signaling pathways, impaired energy metabolism, 
mitochondrial dysfunction, chronic oxidative stress, and 60 
cerebrovascular disease/cerebral hypoperfusion. However, 
the inability to interlink these phenomena under a single 
primary pathogenic mechanism resulted in the emergence 
and propagation of various heavily debated theories, each of 
which focused on how one particular component of AD 65 
could trigger a cascade that contributes to the development 
of all other known abnormalities. 
45 tion/infusion into tissue or blood. 
In some embodiments, the subject technology relates to a 
method of treating Alzheimer's Disease (AD), early-stage 
AD, elevated risk of AD, mild cognitive impairment (MCI), 
or other forms of age-related cognitive decline (collectively 
cognitive decline) in a subject in need thereof. This method 
includes administering to the subject a calcium (Ca2+ )-
release stabilizing molecule, wherein said molecule induces 
reduction, inhibition or reversal of Ca2+ dysregulation in 
brain cells of the subject thereby stabilizing or reducing the 
cognitive decline. In certain embodiments, the molecule is a 
polypeptide, polynucleotide, small molecule or large mol-
ecule. In an embodiment, the molecule is a polypeptide 
selected from immunophilins, junctophilins or calmodulins. 
In another embodiment, the polypeptide molecule is 
FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4, calmodu-
lin 3, a functional fragment thereof or combinations thereof. 
In another embodiment, the molecule is a polynucleotide 
encoding a polypeptide selected from immunophilins, junc-
tophilins or calmodulins. In another embodiment, the poly-
nucleotide molecule is a nucleic acid sequence encoding at 
least one of FKBP1a, FKBP1 b, junctophilin 3, junctophilin 
4, calmodulin 3, a functional fragment thereof or combina-
US 9,464,322 B2 
3 
tions thereof. In some embodiments, the molecule is admin-
istered orally, ophthalmically, nasally, urogentially, rectally, 
dermally, or by way of injection/infusion into tissue or 
blood. 
4 
the one or more genes are differentially expressed in one or 
more brain regions of the patient, said brain regions being 
selected from the group consisting of hippocampal forma-
tion, entorhinal cortex, paleocortex and neocortex. In 
another embodiment, the level of expression of said one or 
more genes is compared to the expression level of one or 
more housekeeping genes. In another embodiment, the level 
of expression of said one or more genes is compared to the 
expression level of one or more genes used as control. 
Additional features and advantages of the subject tech-
nology will be set forth in the description below, and in part 
will be apparent from the description, or may be learned by 
practice of the subject technology. The advantages of the 
subject technology will be realized and attained by the 
In some embodiments, the subject technology relates to a 
method for diagnosing Alzheimer's Disease (AD), early-
stage AD, elevated risk of AD or mild cognitive impairment 
(MCI) in a patient. This method includes (1) obtaining a 
biological sample from the patient, (2) detecting the level of 
expression of one or more calcium-release stabilizing immu- 10 
nophilin, junctophilin and/or calmodulin genes in the bio-
logical sample from said patient, wherein differential 
expression of said one or more genes in the sample as 
compared to control levels of expression of said one or more 
genes is indicative of Alzheimer's Disease (AD), early-stage 
AD, elevated risk of AD or mild cognitive impairment 
(MCI). In an embodiment, the biological sample is blood, 
muscle tissue, brain tissue, peripheral nervous system, cere-
brospinal fluid sample or any tissue sample exhibiting 
significant concentrations of immunophilins, junctophilins 
15 structure particularly pointed out in the written description 
and claims hereof as well as the appended drawings. 
It is to be understood that both the foregoing general 
description and the following detailed description are exem-
plary and explanatory and are intended to provide further 
20 explanation of the subject technology as claimed. 
or calmodulin. In another embodiment, the patient exhibits 
symptoms of Alzheimer's Disease (AD), early-stage AD, 
elevated risk of AD or mild cognitive impairment (MCI) or 
is being treated for Alzheimer's Disease (AD) or mild 
cognitive impairment (MCI). In another embodiment, the 25 
level of expression of one or more genes is determined by a 
nucleic acid polymerization or hybridization technology. In 
another embodiment, at least one of the genes whose level 
of expression is being determined includes FKBP1a, 
FKBP1b, junctophilin 3, junctophilin 4, calmodulin 3 or a 30 
variant thereof. In another embodiment, the one or more 
genes are differentially expressed in one or more brain 
regions of the patient, said brain regions being selected from 
the group consisting of hippocampal formation, entorhinal 
cortex, paleocortex and neocortex. In another embodiment, 35 
the level of expression of said one or more genes is nor-
malized to the expression level of a housekeeping gene as a 
control. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying drawings, which are included to pro-
vide further understanding of the subject technology and are 
incorporated in and constitute a part of this specification, 
illustrate aspects of the subject technology and together with 
the description serve to explain the principles of the subject 
technology. 
FIG. 1 is a bar chart depicting electrophysiological effects 
of unilateral microinjection into one hippocampus of aging 
rats of adena-associated viral (AAV) vector containing the 
open reading frame (ORF) of the Fkbp1b gene. This micro-
injection resulted in overexpression of FKBP1 b mRNA and 
protein (confirmed by qPCR and immunohistochemistry). 
Shown are the quantitative group measures (mean+/-SEM) 
of intracellular electrode recordings of membrane voltage 
responses that are well-established to vary in magnitude 
with the amount of calcium released by intracellular ryano-In some embodiments, the subject technology relates to a 
method for diagnosing Alzheimer's Disease (AD), early-
stage AD, elevated risk of AD or mild cognitive impairment 
(MCI) in a patient. This method includes (1) obtaining a 
biological sample from the patient, (2) detecting the level of 
expression of one or more calcium-release stabilizing immu-
nophilin, junctophilin and/or calmodulin genes in the bio-
logical sample from said patient, wherein differential 
expression of said one or more genes in the sample as 
compared to control levels of expression of housekeeping 
genes, genes whose expressions are known not to change 
with AD, or the same genes obtained from normal subjects 
who do not have AD is indicative of Alzheimer's Disease 
(AD), early-stage AD, elevated risk of AD or mild cognitive 
impairment (MCI). In an embodiment, the biological sample 
40 dine receptors (RyRs); these voltage responses are the 
amplitude of the calcium-dependent medium afterhyperpo-
larization (mAHP) (top panel), amplitude of the calcium-
dependent slow afterhyperpolarization (sAHP) (middle 
panel), and duration of the calcium-dependent slow after-
45 hyperpolarization (sAHP) (bottom panel). The data reveal 
significant differences in these responses in neurons 
recorded from the viral vector-injected hippocampus vs. 
those recorded from the control (non-injected) hippocam-
pus, such that the injected-side neurons exhibit a younger 
50 phenotype (lesser magnitude). Larger amplitude AHPs 
develop with aging and have been correlated with impaired 
is blood, muscle tissue, brain tissue, peripheral nervous 
system, cerebrospinal fluid sample or any tissue sample 55 
exhibiting significant concentrations of immunophilins, 
junctophilins or calmodulin. In another embodiment, the 
patient is exhibiting symptoms of Alzheimer's Disease 
(AD), early-stage AD, elevated risk of AD or mild cognitive 
impairment (MCI) or is being treated for Alzheimer's Dis- 60 
ease (AD) or mild cognitive impairment (MCI). In another 
embodiment, the level of expression of one or more genes is 
determined by a nucleic acid polymerization or hybridiza-
tion technology. In another embodiment, at least one of the 
genes whose level of expression is being determined 65 
includes FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4, 
calmodulin 3 or a variant thereof. In another embodiment, 
memory. 
FIG. 2 shows representative examples of the membrane 
voltage responses (for which the quantitative data are shown 
in FIG. 1). Left Colunm: AHPs that follow an induced burst 
of 4 action potentials (truncated for illustration) in 3 control-
side hippocampal neurons. Right Column: AHPs that follow 
an induced burst of 4 action potentials in 3 injected-side 
hippocampal neurons. TheAHPs are substantially smaller in 
the injected-side neurons, indicating that the overexpression 
ofFKBP1 b has stabilized ryanodine receptors and decreased 
release of calcium from intracellular storage sites. Y-axis: 
membrane holding potential (no significant differences 
between control and injected neurons); X-axis: Time (msec ). 
FIG. 3 shows the AAV-ORF-mediated overexpression of 
FKBP1b/12.6 validated at the protein level. In vivo direct 
microinjection of AAV with Fkbp1b ORF into one hip-
US 9,464,322 B2 
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pocampus (ipsilateral-ipsi) dramatically increased FKBP1 b 
expression compared to the non-injected contralateral hip-
pocampus (contra). Note more intense immunohistochemi-
cal staining of FKBP1 b/12.6 throughout ipsilateral hip-
pocampus (ipsi) (upper panel). More intense staining is also 5 
shown at higher magnification in the CA stratum pyramidale 
(sp) layer (middle panel) and dentate gyrus (DG) (lower 
panel). 
FIG. 4 shows the reversal of Spatial Water Maze Learning 
Deficit in Aged Rats by Hippocampal Microinjection of 10 
Adena-Associated Viral (AAV) Vectors Expressing 
FKBP1b. Panel A is a graph of the water maze learning 
performance of 3 groups of F344 rats, presented as the path 
length (distance in em) traveled to find the submerged 15 
escape platform during 12 training trials and one probe 
(retention) test (Shorter path length=better learning). The 
groups consisted of Aged Controls (22 mo ), Aged AAV-
Fkbp1b injected (22 mo) and Young-Adult Controls (4 mo). 
The agedAAV-Fkbp1b group received bilateral infusions of 20 
AAV expressing the Fkbp1b open reading frame. The other 
two groups received infusions of control AAV expressing 
only green fluorescing protein. Rats were trained by giving 
three learning trials/day over 4 days. On the fifth day a probe 
test was conducted with the escape platform missing to 25 
measure memory retention. Young Controls and Aged-
Fkbp1 b-treated animals performed significantly better than 
Aged Controls on the retention test and on the final two days 
of training. Panel B is the average path length on the 3rd 
training trial of the 3rd and 4th training days. The Aged 30 
AAV-Fkbp1 b group and the Young group performed signifi-
cantly better than Aged controls. (*=p<0.05'**=p<0.001). 
DETAILED DESCRIPTION 
6 
plays a major role in unhealthy brain aging (Gant et a!., J. 
Neuroscience, 31 (5): 1693-1703; February 2011). 
However, the subject technology relates, in part, to an 
unexpected discovery that over expression of the Fkbp1b 
open reading frame (ORF) in the hippocampus of aging rats 
not only counteracts Ca2+ dyshomeostasis, but also 
improves maze learning and/or memory in rats. This unex-
pected discovery suggests that Fkpb1 b and other Ca2+ 
release-stabilizing molecules including immunophilins such 
as Fkbp1a, junctophilins such as junctophilins 3 and 4 or 
clamodulins such as chalmodulin 3, as well as intraneuronal 
calcium channels such as ryanodine receptors (RyRs) and/or 
Inositol trisphosphate receptor (InsP3R) are novel therapeu-
tic molecules and/or targets for interventions aimed at pro-
tection against unhealthy brain aging or Alzheimer's disease 
through stabilization of Ca2 + release mechanisms in brain 
cells. 
Accordingly, in some embodiments, the subject technol-
ogy relates to a method of treating Alzheimer's Disease 
(AD), early-stage AD, elevated risk of AD, mild cognitive 
impairment (MCI), or other forms of age-related cognitive 
decline in a subject in need thereof, by administering to the 
subject a molecule that promotes calcium-release stabiliza-
tion in ryanodine receptors (RyR) and/or inosital triphos-
phate receptors (InsP3R) in brain cells. 
In some embodiments, the subject technology relates to a 
method of treating Alzheimer's Disease (AD), early-stage 
AD, elevated risk of AD, mild cognitive impairment (MCI), 
or other forms of age-related cognitive decline in a subject 
in need thereof, comprising administering to the subject a 
calcium (Ca2 +)-release stabilizing molecule, wherein said 
molecule induces reduction, inhibition or reversal of Ca2+ 
dysregulation in brain cells of the subject. 
In some embodiments, the therapeutic molecule of the 
In the following detailed description, numerous specific 
details are set forth to provide a full understanding of the 
subject technology. It will be apparent, however, to one 
ordinarily skilled in the art that the subject technology may 
35 subject technology includes a polypeptide, polynucleotide, 
small molecule or large molecule. The polypeptide suitable 
for use in this embodiment can be selected from immuno-
philins, junctophilins or calmodulins. More specifically, the 
be practiced without some of these specific details. In other 40 
instances, well-known structures and techniques have not 
been shown in detail so as not to obscure the subject 
technology. 
With aging, multiple Ca2 + -associated electrophysiologi-
cal processes exhibit increased magnitude in hippocampal 45 
pyramidal neurons, including the Ca2 + -dependent slow afte-
rhyperpolarization (sAHP), L-type voltage-gated Ca2+ chan-
nel (L-VGCC) activity, Ca2+-induced Ca2+ release (CICR) 
from ryanodine receptors (RyRs), and Ca2+ transients. This 
pattern of Ca2+ dysregulation correlates with reduced neu- 50 
ronal excitability/plasticity and impaired learning/memory 
and has been proposed to contribute to unhealthy brain aging 
and Alzheimer's disease. However, little is known about the 
underlying molecular mechanisms. 
The inventors have recently found that expression of the 55 
Ca2+-stabilizing molecules, FKBP1a, FKBP1b, junctophi-
lin 3, junctophilin 4, and calmodulin 3 decreases in hip-
pocampus of humans with early-stage AD and that this 
decrease correlates with incipient cognitive dysfunction 
(Blalock eta!., J. Chemical Neuroanatomy 42:118-126; July 60 
2011 ). They have further observed that disrupting FKBP1 b 
function destabilizes Ca2 + homeostasis in hippocampal neu-
rons and is sufficient to induce the aging phenotype of Ca2+ 
dysregulation in young animals. In their study, the inventors 
found that disruption of FKBP1 b recapitulated much of the 65 
Ca2+ -dysregulation aging phenotype in young rat hippocam-
pus, supporting the hypothesis that declining FKBP function 
polypeptide is a full-length amino acid sequence of at least 
one FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4, 
calmodulin 3 or a functional fragment thereof. The poly-
nucleotide suitable for use in this embodiment can be 
polynucleotide encoding a polypeptide selected from immu-
nophilins, junctophilins or calmodulins. More specifically, 
the polynucleotide is a nucleic acid sequence encoding at 
least one of FKBP1a, FKBP1 b, junctophilin 3, junctophilin 
4, calmodulin 3 or a functional fragment thereof. In another 
related embodiment, the molecule is administered orally, 
ophthalmically, nasally, urogentially, rectally, dermally, or 
by way of injection/infusion into tissue or blood. 
In some embodiments, the subject technology relates to a 
method of diagnosing Alzheimer's Disease (AD), early-
stage AD, elevated risk of AD or mild cognitive impairment 
(MCI) in a patient, including: detecting the level of expres-
sion of one or more calcium-release stabilizing immunophi-
lin, junctophilin and/or calmodulin genes in a biological 
sample from said patient, wherein differential expression of 
said one or more genes in the sample as compared to control 
levels of expression of said one or more genes, or to levels 
of expression in the same patient of other control genes 
known not to change with AD, is indicative of Alzheimer's 
Disease (AD), early-stage AD, elevated risk of AD or mild 
cognitive impairment (MCI). 
Definitions: 
To facilitate an understanding of the present subject 
technology, a number of terms and phrases are defined 
below: 
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As used herein, the term "early-stage AD" refers to 
incipient Alzheimer's Disease characterized by at least some 
of and in many cases all of the following signs and symp-
toms: recent memory is impaired; learning and retaining 
new information becomes difficult. Language problems (es-
pecially with word finding), mood swings, and personality 
changes develop. Patient may have progressive difficulty 
with independent activities of daily living (e.g., balancing 
their checkbook, finding their way around, remembering 
where they put things). Abstract thinking, insight, or judg-
ment may be impaired. Patients may respond to loss of 
independence and memory with irritability, hostility, and 
agitation. Functional ability may be further limited by the 
following: Agnosia: Impaired ability to identifY objects 
despite intact sensory function; Apraxia: Impaired ability to 
do previously learned motor activities despite intact motor 
function; and Aphasia: Impaired ability to comprehend or 
use language. Although early-stage AD may not compro-
mise sociability, family members may report strange behav-
ior accompanied by emotional lability. Pathophysiologi-
cally, early-stage AD refers to the beginning stages of 
amyloid ~(A ~)-protein deposit in the brain. Additional 
information related to identifYing early-stage AD are pro-
vided by the American Academy of Neurology (AAN). 
Early stage AD can further be described in terms of the Mini 
Mental State Examination (MMSE) score (See Blalock et 
a!., PNAS 101(7):2173-2178 (2004)). For example, subjects 
can be categorized into the following four groups based on 
MMSE score: "Control" (MMSE>25), "Incipient AD" 
(MMSE=20-26), "Moderate AD" (MMSE=14-19), and 
"SevereAD" (MMSE<14). Earlystage AD can further be 
described as a stage prior to onset of intermediate- or 
late-stage AD. 
In intermediate stage AD, patients are unable to learn or 
recall new information. Memory of remote events is 
reduced, but not totally lost. Patients may require help with 
basic activities of daily living (e.g., bathing, eating, dressing, 
toileting). Personality changes may progress. Patients may 
become irritable, anxious, self-centered, inflexible, or angry 
more easily, or they may become more passive, with a flat 
affect, depression, indecisiveness, lack of spontaneity, or 
general withdrawal from social situations. Behavior disor-
ders may develop: Patients may wander or become suddenly 
and inappropriately agitated, hostile, uncooperative, or 
physically aggressive. By this stage, patients have lost all 
sense of time and place because they cannot effectively use 
normal environmental and social cues. Patients often get 
lost; they may be unable to find their own bedroom or 
bathroom. They remain ambulatory but are at risk of falls or 
accidents secondary to confusion. Altered sensation or per-
ception may culminate in psychosis with hallucinations and 
paranoid and persecutory delusions. Sleep patterns are often 
disorganized. 
In late or severe stage of AD, patients cannot walk, feed 
themselves, or do any other activities of daily living; they 
may become incontinent. Recent and remote memory is 
completely lost. Patients may be unable to swallow. They are 
at risk of malnutrition, pneumonia (especially due to aspi-
ration), and pressure ulcers. Because they depend com-
pletely on others for care, placement in a long-term care 
facility often becomes necessary. Eventually, patients 
become mute. 
As used herein, the term "mild cognitive impairment 
(MCI)" takes its ordinary meaning in the art. MCI mostly 
refers to a condition that is more severe than age-associated 
memory impairment. In MCI, memory is impaired com-
pared with that of age-matched controls, but other cognitive 
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domains and daily function are not affected. Up to 50% of 
patients with mild cognitive impairment develop dementia 
within 3 yr. Normally, patients with MCI once identified are 
monitored for progression to AD. MCI is an intermediate 
stage between the expected cognitive decline of normal 
aging and the more serious decline of dementia. It can 
involve problems with memory, language, thinking and 
judgment that are greater than normal age-related changes. 
Patients with mild cognitive impairment may be aware that 
10 their memory or mental function has "slipped." Their fami-
lies and close friends also may notice a change. But gener-
ally these changes aren't severe enough to interfere with the 
patients' day-to-day life and usual activities. 
As used herein, the term "elevated risk of AD" refers to 
15 situations where a patient suffers from MCI or shows one or 
more of the 10 warning signs of AD (according to the 
American Academy of Neurology guidelines on dementia, 
and the Alzheimer's Association. These 10 warning signs 
are: 1. Memory loss that affects job skills; 2. Difficulty 
20 performing familiar tasks; 3. Problems with language; 4. 
Disorientation to time and place; 5. Poor or decreased 
judgment; 6. Problems with abstract thinking; 7. Misplacing 
things; 8. Changes in mood or behavior; 9. Changes in 
personality; 10. Loss of initiative. Also, it is known that 
25 there is a familial pattern of AD, thus first-degree biological 
relatives of individuals with AD may be at an elevated risk 
of AD than the general population. 
As used herein, a "subject" is preferably a mammal and 
more preferably a hnman, but can be any animal, including 
30 a laboratory animal in the context of a clinical trial or 
screening or activity experiment. Thus, as can be readily 
appreciated by one of ordinary skill in the art, the methods 
of the subject technology are particularly suited to admin-
istration to any animal, particularly a mammal, and includ-
35 ing, but not limited to domestic animals, wild animals and 
research animals. 
As used herein, the term "inhibit" means preventing or 
delaying the onset or progression of one or more clinical 
symptoms of AD. Common early symptoms of Alzheimer's 
40 include confusion, disturbances in short-term memory, prob-
lems with attention and spatial orientation, personality 
changes, language difficulties, unexplained mood swings. 
The term "therapeutically effective amount" is used 
herein to mean an amount or dose of a molecule of the 
45 subject technology that is effective to ameliorate, delay, or 
prevent any of the foregoing symptoms, behaviors or events 
associated with Alzheimer's disease or related neurodegen-
erative disorders including MCI. Alternatively, a therapeu-
tically effective amount is sufficient to cause an improve-
50 ment in a clinically significant condition in the individual. 
As used herein, the phrase "pharmaceutically acceptable" 
refers to molecular entities and compositions that are "gen-
erally regarded as "safe," e.g., that are physiologically 
tolerable and do not typically produce an allergic or similar 
55 untoward reaction, such as gastric upset, dizziness and the 
like, when administered to a human. Preferably, as used 
herein, the term "pharmaceutically acceptable" means 
approved by a regulatory agency of the Federal or a state 
government of listed in the U.S. Pharmacopeia or other 
60 generally recognized pharmacopeia for use in animals, and 
more particularly in humans. 
The term "treat" is used herein to mean to relieve or 
alleviate at least one symptom of a disease in a subject. As 
used herein, the term "treat" also denotes to arrest, delay the 
65 onset (i.e., the period prior to clinical manifestation of a 
disease) and/or reduce the risk of developing or worsening 
a disease. 
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The term "promote" as used herein means to have any 
positive effect or benefit. As used, the term is relative and 
does not necessarily mean to enhance or improve. For 
example, a molecule of the subject technology that stabilizes 
calcium release (as measured electrophysiologically) in 
ryanodine receptors (RyR) and/or inosital triphosphate 
receptors (InsP3R) of neurons and/or muscle cells by at least 
5% as compared to control cells not receiving such molecule 
could still be deemed as having a promoting effect. 
The terms "reference" or "control" as used herein in 
relation to an expression profile refers to a normalized 
pattern of gene or gene product expression or levels of 
expression of certain biomarkers to be used to compare the 
level of expression of the targets (e.g., FKBP1a, FKBP1b, 
junctophilin 3, junctophilin 4, calmodulin 3 or a variant 
thereof) of the subject technology to for the purpose of 
interpreting the expression data obtained from a patient and 
assigning the patient a prognostic or predictive class such as, 
for example, no AD, at risk of AD, elevated risk of AD or 
AD. These biomarkers can be housekeeping genes or pro-
teins whose expressions remain unaffected by AD or clinical 
symptoms of AD or MCI. The biomarkers can also be those 
obtained from one or more healthy individuals known not to 
have AD or clinical symptoms of AD. The biomarkers can 
also be those obtained from a universal control sample 
obtained by pooling a statistically significant number of 
mRNAs or cDNAs from biological samples (e.g., hippocam-
pal cells or tissues) of healthy individuals known to not have 
clinical symptoms of AD or MCI. 
The terms "about" and "approximately" shall generally 
mean an acceptable degree of error or variation for the 
quantity measured given the nature or precision of the 
measurements. Typical, exemplary degrees of error or varia-
tion are within 20 percent (% ), preferably within 10%, and 
more preferably within 5% of a given value or range of 
values. For biological systems, the term "about" refers to an 
acceptable standard deviation of error, preferably not more 
than 2-fold of a give value. Numerical quantities given 
herein are approximate unless stated otherwise, meaning 
that the term "about" or "approximately" can be inferred 
when not expressly stated. 
The term "differential expression" refers to both quanti-
tative as well as qualitative differences in the temporal and 
tissue expression patterns of a gene. For example, a differ-
entially expressed gene may have its expression activated or 
completely inactivated in normal versus disease conditions. 
Such a qualitatively regulated gene may exhibit an expres-
sion pattern within a given tissue or cell type that is 
detectable in either control or disease conditions, but is not 
detectable in both. 
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specific manner. The complex may comprise two strands 
forming a duplex structure, three or more strands forming a 
multi-stranded complex, a single self-hybridizing strand, or 
any combination of these. A hybridization reaction may 
constitute a step in a more extensive process, such as the 
initiation of a PCR reaction, or the enzymatic cleavage of a 
polynucleotide by a ribozyme. 
Hybridization reactions can be performed under condi-
tions of different "stringency". The stringency of a hybrid-
10 ization reaction includes the difficulty with which any two 
nucleic acid molecules will hybridize to one another. Under 
stringent conditions, nucleic acid molecules sharing at least 
60%, 65%, 70%, 75% identity to each other (throughout the 
entire sequence) remain hybridized to each other, whereas 
15 molecules with low percent identity cannot remain hybrid-
ized. A preferred, non-limiting example of highly stringent 
hybridization conditions are hybridization in 6x sodium 
chloride/sodium citrate (SSC) at about 45° C., followed by 
one or more washes in 0.2xSSC, 0.1% SDS at 50° C., 
20 preferably at 55° C., more preferably at 60° C., and even 
more preferably at 65° C. 
As used herein the term "target" refers to the polypeptides 
and polynucleotides of the subject technology including 
immunophilins, junctophilins, calmodulins (whose function 
25 is to stabilize calcium release from calcium channels RyR 
and InsP3R), ryanodine receptors (RyRs) and inosital 
triphosphate receptors (InsP3Rs). Exemplary immunophi-
lins, junctophilins or calmodulins are Fkbp 1 a; Fkbp 1 b vari-
ant (a); Fkbp1b variant (b); Junctophilin 3; Junctophilin 4, 
3° Calmodulin 3. The modulation of quantity or activity of the 
target can result in inhibition, prevention, amelioration, 
treatment or reduction in the aging phenotype of Ca2+ 
dysregulation in a subject with AD, MCI or other cognitive 
impairments. The cDNAand protein sequences of the exem-
35 plary targets of the subject technology can be obtained from 
the National Center for Biotechnology Information (NCBI) 
databases using the accession numbers listed in table below. 
40 Name eDNAAeeession No. Protein Accession No. 
Fkbp1a eDNA: NM_ 000801.4 Protein: NP 000792.1 
Fkbp 1 b variant_a eDNA: NM_ 004116.3 Protein: NP 004107.1 
Fkbp 1 b variant_b eDNA: NM_ 054033.2 Protein: NP _473374.1 
Junetophilin 3 eDNA: NM_ 020655.2 Protein: NP 065706.2 
45 Junetophilin 4 eDNA: NM_ 001146028.1 Protein: 
NP 001139500.1 
Calmodulin 3 eDNA: NM_ 005184.2 Protein: NP 005175.2 
As used herein, the term "panel of targets" includes a 
50 group of targets, the quantity or activity of each member of 
which is correlated with the incidence or risk of incidence of The term "polypeptide" includes a compound of two or 
more subunit amino acids, amino acid analogs, or peptido-
mimetics. The subunits may be linked by peptide bonds. In 
another embodiment, the subunit may be linked by other 
bonds, e.g., ester, ether, etc. As used herein the term "amino 55 
acid" includes either natural and/or unnatural or synthetic 
amino acids, including glycine and both the D or L optical 
isomers, and amino acid analogs and peptidomimetics. A 
peptide of three or more amino acids is commonly referred 
AD or other cognitive impairments. In certain embodiments, 
a panel of targets may include only those targets which are 
either increased or decreased in quantity or activity in 
subjects afflicted with or cells involved in AD or other 
cognitive impairments. In other embodiments, a panel of 
targets may include only those targets present in a specific 
tissue type which are correlated with the incidence or risk of 
incidence of AD or other cognitive impairments. 
to as an oligopeptide. Peptide chains of greater than three or 60 
more amino acids are referred to as a polypeptide or a 
As used herein, the term "small molecule" refers to a 
non-peptidic, non-oligomeric organic compound either syn-
thesized in the laboratory or found in nature. Small mol-
ecules, as used herein, can refer to compounds that are 
"natural product-like", however, the term "small molecule" 
protein. 
"Hybridization" includes a reaction in which one or more 
polynucleotides react to form a complex that is stabilized via 
hydrogen bonding between the bases of the nucleotide 
residues. The hydrogen bonding may occur by Watson-Crick 
base pairing, Hoogstein binding, or in any other sequence-
65 is not limited to "natural product-like" compounds. Rather, 
a small molecule is typically characterized in that it contains 
several carbon-carbon bonds, and has a molecular weight of 
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less than 2000 g/mol, preferably less than 1500 g/mol, 
although this characterization is not intended to be limiting 
for the purposes of the subject technology. Small molecules 
are typically characterized by multiple carbon-carbon bonds 
and may have one or more stereocenters. Examples of 
"small molecules" that occur in nature include, but are not 
limited to, taxol, dynemicin, rapamycin or JTV519 (K201). 
Examples of "small molecules" that are synthesized in the 
laboratory include, but are not limited to, compounds 
described by Tan et a!. ("Stereoselective Synthesis of over 
Two Million Compounds Having Structural Features Both 
Reminiscent of Natural Products and Compatible with Min-
iaturized Cell-Based Assays" J. Am. Chern. Soc. 120:8565, 
1998; incorporated herein by reference). In certain other 
preferred embodiments, natural-product-like small mol-
ecules are utilized. In certain embodiments, the small mol-
ecule is not polymeric or oligomeric. In certain embodi-
ments, the small molecule is not a nucleic acid, protein, or 
peptide. 
As used herein, the term large molecule refers to a drug 
having a molecular weight higher than about 2000 g/mol. 
Exemplary large molecules include synthetic polymers or 
macromolecules with equal to or grater 2000 g/mol of 
molecular weight. In certain embodiments, the large mol-
ecule is not a nucleic acid, protein, or peptide. 
Previously, it was established that several classes of 
molecules, including immunophilins, junctophilins, and 
calmodulin 3 (CALM3) play a necessary role in stabilizing 
Ca2+ release from intracellular stores such as RyRs in 
muscle and cardiac cells. 
In previous studies conducted in the inventors' lab, it was 
shown that the expression of the FKBPlb gene, which 
encodes the FK-506 binding protein lb (FKBPlb, aka 
FKBP12.6), is decreased in hippocampal cells of patients 
with early-stage AD (Blalock et a!., Proc. Nat!. Acad. Sci. 
U.S.A. 101:2173-2178 (2004)) and in aging rats (Kadish et 
a!., J. Neurosci., 29:1805-1816 (2009)). Because the study 
was conducted on hand-dissected frozen hippocampal CAl 
blocks containing both white and gray matter, the authors 
found that it was not possible to distinguish transcriptional 
changes. Further, since heterogeneous cells types/regions 
were mixed together in these studies, tissue-specific changes 
were obscured. No definitive conclusion on the role of 
FKBPl b in cognition and AD could be drawn or suggested. 
In a more recent study (Blalock et a!, 2011 ), a gene 
expression profiling of the laser-captured gray matter 
regions of hippocampal sections revealed that, with AD, 
brain (hippocampal) expression also decreases for a plurality 
of genes that encode proteins that stabilize Ca2+ release from 
RyRs in muscle cells, including FKBPlb, FKBPla, two 
junctophilins and CALM3. Further, it was found that the 
decreased expression of these molecules correlated with 
decreased cognitive function in early-stage AD patients. 
In another more recent study (Gant et a!., 2011 ), it was 
shown that directly manipulating FKBPl b in key brain 
regions of rats, by microinjecting an inactivated viral vector 
containing short interfering RNA against Fkbplb, can 
induce Ca2 + dysregulation (measured electrophysiologi-
cally) related to memory loss and aging phenotype. 
Although the inventors' recent studies established a link 
between the down-regulation or disruption of genes that 
encode Ca2 + release-stabilizing molecules and the Ca2+ 
dysregulation or decreased cognitive function in early-stage 
AD patients, it was unexpected to discover, as shown herein, 
that microinjection of viral vector bearing the open reading 
frame ( orf) of one of the above genes, i.e., the FKBPl b gene, 
into the hippocampus of rats results in overexpression of 
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FKBPlb in regions critical for memory (hippocampus) and 
stabilizes Ca2 + release. It was even more unexpected to 
discover that this reversal of Ca2 + dysregulation resulted in 
an improved memory. Thus, according to the subject tech-
nology, the stabilization of Ca2+ release from the calcium 
receptors such as RyRs or InsP3R, as observed in the present 
disclosure, leads to the reversal of Ca2 + dysregulation and 
indicates that both the receptors and molecules that stabilize 
these receptors can be used as targets for developing diag-
10 nostic and/or therapeutic means for treating or inhibiting 
memory loss, AD, MCI, and other cognitive or memory 
impairments. 
Ryanodine receptors (RyRs) form a class of intracellular 
calcium channels in various forms of excitable animal tissue 
15 like muscles and neurons. It is the major cellular mediator of 
calcium-induced calcium release (CICR) in animal cells. 
There are multiple isoforms of ryanodine receptors includ-
ing: RyRl (Entrez ID No. 6261; Hugo ID. No. 10483; Omim 
ID. No. 180901; RefSeq ID No. NM_000540; and UniProt 
20 ID No. P21817); RyR2 (Entrez ID No. 6262; Hugo ID. No. 
10484; OmimiD. No.180902; RefSeqiDNo. NM_001035; 
and UniProt ID No. Q92736); and RyR3 (Entrez ID No. 
6263; Hugo ID. No. 10485; Omim ID. No. 180903; RefSeq 
ID No. NM_001036; and UniProt ID No. Q15413) which is 
25 expressed more widely, but especially in the brain. 
Inositol trisphosphate receptor (InsP3R) is a membrane 
glycoprotein complex acting as Ca2 + channel activated by 
inositol trisphosphate (InsP3). InsP3R is very diverse among 
organisms, and is necessary for the control of cellular and 
30 physiological processes including cell division, cell prolif-
eration, apoptosis, fertilization, development, behavior, 
learning and memory. Inositol triphosphate receptor repre-
sents a dominant second messenger leading to the release of 
Ca2+ from intracellular store sites. There is evidence sug-
35 gesting that InsP3R plays an important role in the conver-
sion of external stimuli to intracellular Ca2+ signals charac-
terized by complex patterns relative to both space and time, 
for example, Ca2 + waves and oscillations. The InsP3 recep-
tor was first purified from rat cerebellum. There are multiple 
40 isoforms of ryanodine receptors including: InsP3Rl (also 
abbreviated as ITPRl; Entrez ID No. 3708; Hugo ID. No. 
6180; Omim ID. No. 147265; RefSeq ID No. NM_002222; 
and UniProt ID No. Q14643); InsP3R2 (also abbreviated as 
ITPR2; Entrez ID No. 3709; Omim ID. No. 600144; RefSeq 
45 ID No. NM_002223; and UniProt ID No. Q14571); and 
InsP3R3 (also abbreviated as ITPR3; Entrez ID No. 3710; 
Hugo ID. No. 6182; Omim ID. No. 147267; RefSeq ID No. 
NM_002224; and UniProt ID No. Q14573). 
In one embodiment, the subject technology provides a 
50 method for diagnosing AD, early-stage AD, mild cognitive 
impairment (MCI) or elevated risk of AD, comprising taking 
a biopsy sample from muscle tissue or any other tissue 
exhibiting significant concentrations of immunophilins, 
junctophilins or calmodulin3, measuring in that sample 
55 RNA expression (content, e.g., by qPCR, microarrays or 
newer methods) for a plurality of genes that encode Ca2+ 
release-stabilizing molecules (those noted above), also mea-
suring in the same sample RNA content for a number of 
genes that do not change in brain or muscle with AD, and 
60 comparing the ratio of expression of Ca2 + release-stabilizing 
genes to expression of AD-insensitive genes, relative to a 
normalizing/scaling factor (e.g., average signal of all genes) 
in the same sample. Alternatively, the ratio of Ca2 + stabi-
lizing genes could be compared to values for those same 
65 Ca2+ stabilizing genes in normal subjects, which would be 
obtained by averaging across a statistically significant num-
ber of control subjects that did not exhibit AD or cognitive 
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decline. Several statistical techniques well-known in the 
field will allow determination of the degree of deviation of 
the expression of Ca2 + release-stabilizing genes from 
expression of AD-insensitive genes relative to a normalizing 
baseline, or from averages of Ca2 + release-stabilizing genes 
in non-AD subjects, thereby providing a quantitative index 
14 
a target gene of the subject technology or a nucleic acid 
molecule encoding a polypeptide target of the subject tech-
nology can be isolated using standard hybridization and 
cloning techniques (e.g., as described in Sambrook, J., 
Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Labo-
ratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, 
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 
N.Y., 1989). 
of deviation that can be used to estimate AD risk or 
progression. With clinical experience, estimates based on 
this index will be further validated and become increasingly 
precise. 
In another embodiment, the subject technology relates to 
a method for treating AD, early-stage AD, mild cognitive 
impairment (MCI), other forms of aging-related cognitive 
decline or elevated risk of AD, comprising enhancing activ-
ity of one or more Ca2 + release-stabilizing molecules in a 
subject diagnosed with one of the above conditions by 
injecting the subject in the hippocampus and/or other 
affected brain regions with a quantity of inactivated virus 
that has been molecularly engineered to overexpress one or 
A nucleic acid of the subject technology can be amplified 
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using eDNA, mRNA or alternatively, genomic DNA, as a 
template and appropriate oligonucleotide primers according 
to standard PCR amplification techniques. The nucleic acid 
so amplified can be cloned into an appropriate vector and 
15 characterized by DNA sequence analysis. Furthermore, oli-
gonucleotides corresponding to target nucleotide sequences, 
or nucleotide sequences encoding a target of the subject 
technology can be prepared by standard synthetic tech-
niques, e.g., using an automated DNA synthesizer. 
In another embodiment, an isolated nucleic acid molecule 
of the subject technology comprises a nucleic acid molecule 
which is a complement of the nucleotide sequence of a target 
of the subject technology or a portion of any of these 
nucleotide sequences. A nucleic acid molecule which is 
a plurality of genes encoding Ca2 + release-stabilizing mol- 20 
ecules, as mentioned above, and assessing the treated subject 
over time for improved performance on cognitive/neurop-
sychological tests. Alternative embodiments of this subject 
technology include other delivery methods (eg, non-viral-
mediated cellular uptake, microinfusions, targeted pharma-
cological delivery, etc.) of nucleotide sequences that will 
increase expression of Ca2+ -stabilizing molecules in cells in 
brain regions affected by AD. Other alternative embodi-
ments include methods that do not rely on gene expression, 
but which enhance activity of Ca2+ release-stabilizing mol-
ecules through post-translational modifications, micro-
RNAs or pharmacological targeting of Ca2+ release-stabi-
lizing molecules or their inhibitors. 
25 complementary to such a nucleotide sequence is one which 
is sufficiently complementary to the nucleotide sequence 
such that it can hybridize to the nucleotide sequence, thereby 
forming a stable duplex. 
The nucleic acid molecule of the subject technology, 
Various aspects of the subject technology are described in 
further detail in the following subsections: 
30 moreover, can comprise only a portion of the nucleic acid 
sequence of a target nucleic acid of the subject technology, 
or a gene encoding a target polypeptide of the subject 
technology, for example, a fragment which can be used as a 
probe or primer. The probe/primer typically comprises sub-
I. Isolated Nucleic Acid Molecules Encoding Ca2+ Release-
Stabilizing Molecules 
35 stantially purified oligonucleotide. The oligonucleotide typi-
cally comprises a region of nucleotide sequence that hybrid-
izes under stringent conditions to at least about 7 or 15, 
preferably about 20 or 25, more preferably about 50, 75, One aspect of the subject technology pertains to isolated 
nucleic acid molecules that either themselves are the genetic 
targets (e.g., variants of any of the Ca2 + release-stabilizing 40 
molecules disclosed herein) of the subject technology, or 
which encode the polypeptide targets of the subject tech-
nology, or functional fragments thereof. Another aspect of 
the subject technology relates to using the nucleic acid 
sequences of Fkbp1a, Fkbp1 b variant_a, Fkbp1 b variant_b, 45 
Junctophilin 3, Junctophilin 4 and Calmodulin 3 to obtain 
variant molecules encoding proteins that have similar activ-
ity, i.e., calcium release-stabilizing activity for ryanodine 
receptors (RyRs), inosital triphosphate receptors (InsP3Rs). 
Another aspect of the subject technology pertains to isolated 50 
nucleic acid fragments sufficient for use as hybridization 
probes to identifY the nucleic acid molecules encoding the 
targets of the subject technology in a sample, as well as 
nucleotide fragments for use as PCR primers for the ampli-
fication or mutation of the nucleic acid molecules which 55 
encode the targets of the subject technology. As used herein, 
the term "nucleic acid molecule" is intended to include DNA 
molecules (e.g., eDNA or genomic DNA) and RNA mol-
ecules (e.g., mRNA) and analogs of the DNA or RNA 
generated using nucleotide analogs. The nucleic acid mol-
ecule can be single-stranded or double-stranded, but pref-
erably is double-stranded DNA. 
A nucleic acid molecule of the subject technology, e.g., a 
variant ofFKBP1 b, can be isolated using standard molecular 
biology techniques and the sequence information provided 
herein. Using all or portion of the nucleic acid sequence of 
the FKBP gene, e.g., the FKBP1 b as a hybridization probe, 
100, 125, 150, 175,200, 225,250, 275,300, 325,350, 400 
or more consecutive nucleotides of a target nucleic acid, or 
a nucleic acid encoding a target polypeptide of the subject 
technology. 
Probes based on the nucleotide sequence of a target gene 
or of a nucleic acid molecule encoding a target polypeptide 
of the subject technology can be used to detect transcripts or 
genomic sequences corresponding to the target gene( s) 
and/or target polypeptide(s) of the subject technology. In 
preferred embodiments, the probe comprises a label group 
attached thereto, e.g., the label group can be a radioisotope, 
a fluorescent compound, an enzyme, or an enzyme co-factor. 
Such probes can be used as a part of a diagnostic test kit for 
identifying cells or tissue which misexpress (e.g., over- or 
under-express) a target polypeptide of the subject technol-
ogy, or which have greater or fewer copies of a target gene 
of the subject technology. For example, a level of a target 
polypeptide-encoding nucleic acid in a sample of cells from 
a subject may be detected, the amount of mRNA transcript 
of a gene encoding a target polypeptide may be determined, 
or the presence of mutations or deletions of a target gene of 
60 the subject technology may be assessed. 
The subject technology further encompasses nucleic acid 
molecules that differ from the nucleic acid sequences of the 
gene of the Ca2+ release-stabilizing molecules of the subject 
technology, e.g., FKBP1 b gene, due to degeneracy of the 
65 genetic code and which thus encode the same proteins as 
those encoded by the gene of the Ca2 + release-stabilizing 
molecules, e.g., FKBP1 b gene. 
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It will be appreciated by those skilled in the art that DNA 
sequence polymorphisms can lead to changes in the amino 
acid sequences of the proteins encoded by the genes of the 
Ca2+ release-stabilizing molecules of the instant disclosure. 
Such genetic polymorphism in, for example, the FKBP1 b 
gene, may exist among individuals within a population due 
16 
In addition to naturally-occurring allelic variants of the 
target gene and gene encoding a target protein of the subject 
technology sequences that may exist in the population, the 
skilled artisan will further appreciate that changes can be 
introduced by mutation into the nucleotide sequences of the 
target genes or genes encoding the target proteins of the 
subject technology, thereby leading to changes in the amino 
acid sequence of the encoded proteins, without altering the 
functional activity of these proteins. For example, nucleotide 
to natural allelic variation. An allele is one of a group of 
genes which occur alternatively at a given genetic locus. In 
addition it will be appreciated that DNA polymorphisms that 
affect RNA expression levels can also exist that may affect 
the overall expression level of that gene (e.g., by affecting 
regulation or degradation). As used herein, the phrase 
"allelic variant" includes a nucleotide sequence which 
occurs at a given locus or to a polypeptide encoded by the 
nucleotide sequence. As used herein, the terms "gene" and 
"recombinant gene" refer to nucleic acid molecules which 
include an open reading frame encoding a target polypeptide 
10 substitutions leading to amino acid substitutions at "non-
essential" amino acid residues can be made. A "non-essen-
tial" amino acid residue is a residue that can be altered from 
the wild-type sequence of a protein without altering the 
biological activity, whereas an "essential" amino acid resi-
of the subject technology. 
15 due is required for biological activity. For example, amino 
acid residues that are conserved among allelic variants or 
homologs of a gene (e.g., among homologs of a gene from 
different species) are predicted to be particularly uname-
nable to alteration. 
Accordingly, another aspect of the subject technology 
pertains to nucleic acid molecules encoding a target protein 
of the subject technology that contain changes in amino acid 
residues that are not essential for activity. Such proteins 
differ in amino acid sequence from the target proteins 
Nucleic acid molecules corresponding to natural allelic 
variants and homologues of the gene to the Ca2+ release- 20 
stabilizing molecules or genes encoding the Ca2+ release-
stabilizing molecules can be isolated based on their homol-
ogy to the gene of the Ca2+ release-stabilizing molecules 
using the cDNAs disclosed herein, or a portion thereof, as a 
hybridization probe according to standard hybridization 
techniques under stringent hybridization conditions. Nucleic 
acid molecules corresponding to natural allelic variants and 
homologues of the target genes of the subject technology can 
further be isolated by mapping to the same chromosome or 
locus as the target genes or genes encoding the target 
proteins of the subject technology. 
25 encoded by the gene of the Ca2+ release-stabilizing mol-
ecules yet retain the same biological activity. In one embodi-
ment, the protein comprises an amino acid sequence at least 
about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 
more homologous or identical to a target protein of the 
30 subject technology. 
In another embodiment, an isolated nucleic acid molecule 
An isolated nucleic acid molecule encoding a protein 
homologous to a target protein of the subject technology can 
be created by introducing one or more nucleotide substitu-
tions, additions or deletions into the nucleotide sequence of 
35 the gene encoding the target protein, such that one or more 
amino acid substitutions, additions or deletions are intro-
duced into the encoded protein. Mutations can be introduced 
into the gene of the Ca2+ release-stabilizing molecules, e.g., 
FKBP1 b gene, of the subject technology by standard tech-
of the subject technology is at least 15, 20, 25, 30, 50, 100, 
150,200,250,300,350,400,450,500,550,600,650,700, 
750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 
1500, 1600, 1700, 1800, 1900, 2000 or more nucleotides in 
length and hybridizes under stringent conditions to a nucleic 
acid molecule corresponding to a nucleotide sequence of a 
target gene or gene encoding a target protein of the subject 
technology. As used herein, the term "hybridizes under 
stringent conditions" is intended to describe conditions for 
hybridization and washing under which nucleotide 
sequences at least 60% sequence identity (over their entire 
lengths) to each other typically remain hybridized to each 
other. Generally, percent homology or identity is based on 
two polynucleotide strands that are comparable in length the 
percent value reflects homology throughout the length of the 
two strands. Preferably, the conditions are such that 
sequences at least about 70%, more preferably at least about 
80%, even more preferably at least about 85% or 90% 50 
homologous to each other (over their entire lengths or 
throughout their lengths) typically remain hybridized to each 
other. Such stringent conditions are known to those skilled 
40 niques, such as site-directed mutagenesis and PCR -mediated 
mutagenesis. Preferably, conservative amino acid substitu-
tions are made at one or more predicted non-essential amino 
acid residues. A "conservative amino acid substitution" is 
one in which the amino acid residue is replaced with an 
45 amino acid residue having a similar side chain. Families of 
amino acid residues having similar side chains have been 
defined in the art. These families include amino acids with 
basic side chains (e.g., lysine, arginine, histidine), acidic 
in the art and can be found in Current Protocols in Molecular 
Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A 55 
preferred, non-limiting example of stringent hybridization 
conditions are hybridization in 6x sodium chloride/sodium 
citrate (SSC) at about 45° C., followed by one or more 
washes in 0.2xSSC, 0.1% SDS at 50° C., preferably at 55° 
C., more preferably at 60° C., and even more preferably at 60 
65° C. Preferably, an isolated nucleic acid molecule of the 
subject technology that hybridizes under stringent condi-
tions to the sequence of the gene of the Ca2 + release-
stabilizing molecules, e.g., FKBP1b gene. As used herein, a 
"naturally-occurring" nucleic acid molecule includes an 65 
RNA or DNA molecule having a nucleotide sequence that 
occurs in nature (e.g. encodes a natural protein). 
side chains (e.g., aspartic acid, glutamic acid), uncharged 
polar side chains (e.g., glycine, asparagine, glutamine, ser-
ine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., 
alanine, valine, leucine, isoleucine, proline, phenylalanine, 
methionine, tryptophan), beta-branched side chains (e.g., 
threonine, valine, isoleucine) and aromatic side chains (e.g., 
tyrosine, phenylalanine, tryptophan, histidine). Alterna-
tively, mutations can be introduced randomly along all or 
part of a coding sequence of a gene of the subject technol-
ogy, such as by saturation mutagenesis, and the resultant 
mutants can be screened for biological activity to identifY 
mutants that retain activity. Following mutagenesis, the 
encoded protein can be expressed recombinantly and the 
activity of the protein can be determined. 
In yet another embodiment, the nucleic acid molecules of 
the present subject technology can be modified at the base 
moiety, sugar moiety or phosphate backbone to improve, 
e.g., the stability, hybridization, or solubility of the mol-
ecule. For example, the deoxyribose phosphate backbone of 
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the nucleic acid molecules can be modified to generate 
peptide nucleic acids (see Hyrup B. eta!. (1996) Bioorganic 
& Medicinal Chemistry 4 (1): 5-23). As used herein, the 
terms "peptide nucleic acids" or "PNAs" refer to nucleic 
acid mimics, e.g., DNA mimics, in which the deoxyribose 
phosphate backbone is replaced by a pseudopeptide back-
bone and only the four natural nucleobases are retained. The 
neutral backbone of PNAs has been shown to allow for 
specific hybridization to DNA and RNA under conditions of 
low ionic strength. The synthesis of PNA oligomers can be 
performed using standard solid phase peptide synthesis 
protocols as described in Hyrup B. et a!. (1996) supra; 
Perry-O'Keefe et a!. Proc. Nat!. Acad. Sci. 93: 14670-675. 
In other embodiments, the oligonucleotide may include 
other appended groups such as peptides (e.g., for targeting 
host cell receptors in vivo), or agents facilitating transport 
across the cell membrane (see, e.g., Letsinger eta!. (1989) 
Proc. Nat!. Acad. Sci. USA 86:6553-6556; Lemaitre et a!. 
(1987) Proc. Nat!. Acad. Sci. USA 84:648-652; PCT Pub-
lication No. W088/09810) or the blood-brain barrier (see, 
e.g., PCT Publication No. W089/10134). In addition, oli-
gonucleotides can be modified with hybridization-triggered 
cleavage agents (See, e.g., Krol eta!. (1988) Bio-Techniques 
6:958-976) or intercalating agents. (See, eg., Zon (1988) 
Pharm. Res. 5:539-549). To this end, the oligonucleotide 
may be conjugated to another molecule, (e.g., a peptide, 
hybridization triggered cross-linking agent, transport agent, 
or hybridization-triggered cleavage agent). Finally, the oli-
gonucleotide may be detectably labeled, either such that the 
label is detected by the addition of another reagent (e.g. a 
substrate for an enzymatic label), or is detectable immedi-
ately upon hybridization of the nucleotide (e.g., a radioac-
tive label or a fluorescent label (e.g., a molecular beacon, as 
described in U.S. Pat. No. 5,876,930. 
II. Isolated Proteins and Antibodies 
One aspect of the subject technology pertains to isolated 
target proteins i.e., the Ca2+ release-stabilizing molecules, 
e.g., Fkbp1a, Fkbp1 b variant_a, Fkbp1 b variant_b, Juncto-
philin 3, Junctophilin 4 and Calmodulin 3, and biologically 
or functionally active portions thereof suitable for use as 
therapeutic molecules for stabilizing calcium release from 
ryanodine receptors (RyRs), inosital triphosphate receptors 
(InsP3Rs). Alternatively, the isolated target proteins i.e., the 
Ca2+ release-stabilizing molecules, e.g., Fkbp1a, Fkbp1 b 
variant_a, Fkbp1 b variant_b, Junctophilin 3, Junctophilin 4 
and Calmodulin 3, and biologically or functionally active 
portions thereof suitable for use are used as immunogens to 
raise anti-target protein antibodies. In one embodiment, 
native target proteins can be isolated from cells or tissue 
sources by an appropriate purification scheme using stan-
dard protein purification techniques. In another embodi-
ment, target proteins are produced by recombinant DNA 
techniques. Alternative to recombinant expression, a target 
protein or polypeptide can be synthesized chemically using 
standard peptide synthesis techniques. 
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protein (also referred to herein as a "contaminating pro-
tein"), more preferably less than about 20% of non-target 
protein, still more preferably less than about 10% of non-
target protein, and most preferably less than about 5% 
non-target protein. When the target protein or biologically 
active portion thereof is recombinantly produced, it is also 
preferably substantially free of culture medium, i.e., culture 
medium represents less than about 20%, more preferably 
less than about 10%, and most preferably less than about 5% 
10 of the volume of the protein preparation. 
The language "substantially free of chemical precursors 
or other chemicals" includes preparations of target protein in 
which the protein is separated from chemical precursors or 
other chemicals which are involved in the synthesis of the 
15 protein. In one embodiment, the language "substantially free 
of chemical precursors or other chemicals" includes prepa-
rations of protein having less than about 30% (by dry 
weight) of chemical precursors or non-protein chemicals, 
more preferably less than about 20% chemical precursors or 
20 non-protein chemicals, still more preferably less than about 
10% chemical precursors or non-protein chemicals, and 
most preferably less than about 5% chemical precursors or 
non-protein chemicals. 
As used herein, a "biologically active portion" or "func-
25 tiona! fragment" (as used interchangeably) of a target pro-
tein includes a fragment of a target protein comprising 
amino acid sequences sufficiently homologous to or derived 
from the amino acid sequence of the target protein, which 
include fewer amino acids than the full length target pro-
30 teins, and exhibit at least one activity of a target protein, i.e., 
Ca2+ release-stabilizing activity on RyRs or InsP3Rs. Typi-
cally, biologically active portions comprise a domain or 
motif with at least one activity of the target protein. A 
biologically active portion of a target protein can be a 
35 polypeptide which is, for example, 10, 25, 50, 100, 200 or 
more amino acids in length. Biologically active portions of 
a target protein can be used as targets for developing agents 
which modulate a target protein-mediated activity. 
In a preferred embodiment, target protein is encoded by 
40 the gene of the Ca2+ release-stabilizing molecules. In other 
embodiments, the target protein is substantially homologous 
to a target protein encoded by the genes of the Ca2+ 
release-stabilizing molecules, e.g., FKBP1 b gene, and 
retains the functional activity of the target protein, yet differs 
45 in amino acid sequence due to natural allelic variation or 
mutagenesis, as described in detail in subsection I above. 
Accordingly, in another embodiment, the target protein is a 
protein which comprises an amino acid sequence with at 
least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 
50 98% or more sequence identity to the amino acid sequence 
encoded by the genes of the Ca2 + release-stabilizing mol-
ecules, e.g., FKBP1b gene. 
To determine the percent identity of two amino acid 
sequences or of two nucleic acid sequences, the sequences 
55 are aligned for optimal comparison purposes (e.g., gaps can 
be introduced in one or both of a first and a second amino An "isolated" or "purified" protein or biologically active 
portion thereof is substantially free of cellular material or 
other contaminating proteins from the cell or tissue source 
from which the target protein is derived, or substantially free 
from chemical precursors or other chemicals when chemi- 60 
cally synthesized. The language "substantially free of cel-
lular material" includes preparations of target protein in 
which the protein is separated from cellular components of 
the cells from which it is isolated or recombinantly pro-
duced. In one embodiment, the language "substantially free 65 
of cellular material" includes preparations of target protein 
having less than about 30% (by dry weight) of non-target 
acid or nucleic acid sequence for optimal aligument and 
non-homologous sequences can be disregarded for compari-
son purposes). In a preferred embodiment, the length of a 
reference sequence aligned for comparison purposes is at 
least 30%, preferably at least 40%, more preferably at least 
50%, even more preferably at least 60%, and even more 
preferably at least 70%, 80%, or 90% of the length of the 
reference sequence. The amino acid residues or nucleotides 
at corresponding amino acid positions or nucleotide posi-
tions are then compared. When a position in the first 
sequence is occupied by the same amino acid residue or 
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The non-target polypeptide can be fused to theN-terminus 
or C-terminus of the target polypeptide. 
For example, in one embodiment, the fusion protein is a 
GST-target fusion protein in which the target sequences are 
fused to the C-terminus of the GST sequences. Such fusion 
proteins can facilitate the purification of recombinant target 
proteins. 
In another embodiment, the fusion protein is a target 
protein containing a heterologous signal sequence at its 
nucleotide as the corresponding pos1t!on in the second 
sequence, then the molecules are identical at that position (as 
used herein amino acid or nucleic acid "identity" is equiva-
lent to amino acid or nucleic acid "homology"). The percent 
identity between the two sequences is a function of the 
number of identical positions shared by the sequences, 
taking into account the number of gaps, and the length of 
each gap, which need to be introduced for optimal alignment 
of the two sequences. 
The comparison of sequences and determination of per-
cent identity between two sequences can be accomplished 
using a mathematical algorithm. In a preferred embodiment, 
the percent identity between two amino acid sequences is 
determined using the Needleman and Wunsch (J. Mat. Bioi. 
(48):444-453 (1970)) algorithm which has been incorpo-
rated into the GAP program in the GCG software package, 
using either a Blossom 62 matrix or a PAM250 matrix, and 
10 N-terminus. In certain host cells (e.g., mammalian host 
cells), expression and/or secretion of target proteins can be 
increased through use of a heterologous signal sequence. 
Such signal sequences are well known in the art. 
The target fusion proteins of the subject technology can be 
a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight 
of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, 
the percent identity between two nucleotide sequences is 
determined using the GAP program in the GCG software 
package, using a NWSgapdna.CMP matrix and a gap weight 
15 incorporated into pharmaceutical compositions and admin-
istered to a subject in vivo, as described herein. The target 
fusion proteins can be used to affect the bioavailability of a 
target protein substrate. Use of target fusion proteins may be 
useful therapeutically for the treatment of disorders (e.g., 
20 AD, MCI or other cognitive impairments) caused by, for 
example, (i) aberrant modification or mutation of a gene 
encoding a target protein; (ii) mis-regulation of the target 
protein-encoding gene; and (iii) aberrant post-translational 
of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, modification of a target protein. 
Moreover, the target-fusion proteins of the subject tech-
nology can be used as immunogens to produce anti-target 
protein antibodies in a subject, to purifY target protein 
ligands and in screening assays to identifY molecules which 
inhibit the interaction of a target protein with a target protein 
or 6. In another embodiment, the percent identity between 25 
two amino acid or nucleotide sequences is determined using 
the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 
(1989)) which has been incorporated into the ALIGN pro-
gram (version 2.0), using a PAM120 weight residue table, a 
gap length penalty of 12 and a gap penalty of 4. 30 substrate. 
The nucleic acid and protein sequences of the present 
subject technology can further be used as a "query 
sequence" to perform a search against public databases to, 
for example, identifY other family members or related 
sequences. Such searches can be performed using the 35 
NBLAST and XBLAST programs (version 2.0) of Altschul, 
eta!. (1990) J. Mol. Bioi. 215:403-10. BLAST nucleotide 
searches can be performed with the NBLAST program, 
score= 100, wordlength= 12 to obtain nucleotide sequences 
homologous to nucleic acid molecules of the subject tech- 40 
nology. BLAST protein searches can be performed with the 
XBLAST program, score=50, wordlength=3 to obtain 
amino acid sequences homologous to target protein mol-
ecules of the subject technology. To obtain gapped align-
ments for comparison purposes, Gapped BLAST can be 45 
utilized as described in Altschul eta!., (1997) Nucleic Acids 
Res. 25(17):3389-3402. When utilizing BLAST and Gapped 
BLAST programs, the default parameters of the respective 
programs (e.g., XBLAST and NBLAST) can be used. 
The subject technology also provides chimeric or fusion 50 
target proteins. As used herein, a target "chimeric protein" or 
"fusion protein" comprises a target polypeptide operatively 
linked to a non-target polypeptide. A "target polypeptide" 
includes a polypeptide having an amino acid sequence 
encoded by the genes of the Ca2+ release-stabilizing mol- 55 
ecules, e.g., FKBP1b gene, whereas a "non-target polypep-
tide" includes a polypeptide having an amino acid sequence 
corresponding to a protein which is not substantially 
homologous to the target protein, e.g., a protein which is 
different from target protein and which is derived from the 60 
same or a different organism. Within a target fusion protein 
the polypeptide can correspond to all or a portion of a target 
protein. In a preferred embodiment, a target fusion protein 
comprises at least one biologically active portion of a target 
protein. Within the fusion protein, the term "operatively 65 
linked" is intended to indicate that the target polypeptide and 
the non-target polypeptide are fused in-frame to each other. 
Preferably, a target chimeric or fusion protein of the 
subject technology is produced by standard recombinant 
DNA techniques. For example, DNA fragments coding for 
the different polypeptide sequences are ligated together 
in-frame in accordance with conventional techniques, for 
example by employing blunt-ended or stagger-ended termini 
for ligation, restriction enzyme digestion to provide for 
appropriate termini, filling-in of cohesive ends as appropri-
ate, alkaline phosphatase treatment to avoid undesirable 
joining, and enzymatic ligation. In another embodiment, the 
fusion gene can be synthesized by conventional techniques 
including automated DNA synthesizers. Alternatively, PCR 
amplification of gene fragments can be carried out using 
anchor primers which give rise to complementary overhangs 
between two consecutive gene fragments which can subse-
quently be annealed and reamplified to generate a chimeric 
gene sequence (see, for example, Current Protocols in 
Molecular Biology, eds. Ausubel et a!. John Wiley & Sons: 
1992). Moreover, many expression vectors are commer-
cially available that already encode a fusion moiety (e.g., a 
GST polypeptide). A target protein-encoding nucleic acid 
can be cloned into such an expression vector such that the 
fusion moiety is linked in-frame to the target protein. 
A signal sequence can be used to facilitate secretion and 
isolation of the secreted protein or other proteins of interest. 
Signal sequences are typically characterized by a core of 
hydrophobic amino acids which are generally cleaved from 
the mature protein during secretion in one or more cleavage 
events. Such signal peptides contain processing sites that 
allow cleavage of the signal sequence from the mature 
proteins as they pass through the secretory pathway. Thus, 
the subject technology pertains to the described polypeptides 
having a signal sequence, as well as to polypeptides from 
which the signal sequence has been proteolytically cleaved 
(i.e., the cleavage products). In one embodiment, a nucleic 
acid sequence encoding a signal sequence can be operably 
linked in an expression vector to a protein of interest, such 
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as a protein which is ordinarily not secreted or is otherwise 
difficult to isolate. The signal sequence directs secretion of 
the protein, such as from a eukaryotic host into which the 
expression vector is transformed, and the signal sequence is 
subsequently or concurrently cleaved. The protein can then 
be readily purified from the extracellular medium by art 
recognized methods. Alternatively, the signal sequence can 
be linked to the protein of interest using a sequence which 
facilitates purification, such as with a GST domain. 
The present subject technology also pertains to variants of 
the target proteins of the subject technology which function 
as either agonists (mimetics) or as antagonists to the target 
proteins. Variants of the target proteins can be generated by 
mutagenesis, e.g., discrete point mutation or truncation of a 
target protein. An agonist of the target proteins can retain 
substantially the same, or a subset, of the biological activi-
ties of the naturally occurring form of a target protein. An 
antagonist of a target protein can inhibit one or more of the 
activities of the naturally occurring form of the target protein 
by, for example, competitively modulating an activity of a 
target protein. Thus, specific biological effects can be elic-
ited by treatment with a variant of limited function. In one 
embodiment, treatment of a subject with a variant having a 
subset of the biological activities of the naturally occurring 
form of the protein has fewer side effects in a subject relative 
to treatment with the naturally occurring form of the target 
protein. 
Variants of a target protein which function as either target 
protein agonists (mimetics) or as target protein antagonists 
can be identified by screening combinatorial libraries of 
mutants, e.g., truncation mutants, of a target protein for 
target protein agonist or antagonist activity. In one embodi-
ment, a variegated library of target protein variants is 
generated by combinatorial mutagenesis at the nucleic acid 
level and is encoded by a variegated gene library. A varie-
gated library of target protein variants can be produced by, 
for example, enzymatically ligating a mixture of synthetic 
oligonucleotides into gene sequences such that a degenerate 
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from reformed duplexes by treatment with S1 nuclease, and 
ligating the resulting fragment library into an expression 
vector. By this method, an expression library can be derived 
which encodes N-terminal, C-terminal and internal frag-
ments of various sizes of the target protein. 
Several techniques are known in the art for screening gene 
products of combinatorial libraries made by point mutations 
or truncation, and for screening eDNA libraries for gene 
products having a selected property. The most widely used 
10 techniques, which are amenable to high through-put analy-
sis, for screening large gene libraries typically include 
cloning the gene library into replicable expression vectors, 
transforming appropriate cells with the resulting library of 
vectors, and expressing the combinatorial genes under con-
15 ditions in which detection of a desired activity facilitates 
isolation of the vector encoding the gene whose product was 
detected. Recursive ensemble mutagenesis (REM), a tech-
nique which enhances the frequency of functional mutants in 
the libraries, can be used in combination with the screening 
20 assays to identifY target variants (Arkin and Yourvan (1992) 
Proc. Nat!. Acad. Sci. USA 89:7811-7815; Delgrave eta!. 
(1993) Protein Engineering 6(3):327-331). 
An isolated target protein, or a portion or fragment 
thereof, can be used as an immunogen to generate antibodies 
25 that bind target proteins using standard techniques for poly-
clonal and monoclonal antibody preparation. A full-length 
target protein can be used or, alternatively, the subject 
technology provides antigenic peptide fragments of these 
proteins for use as immunogens. The antigenic peptide of a 
30 target protein comprises at least 8 amino acid residues of an 
amino acid sequence encoded by the FKBP1b gene, and 
encompasses an epitope of a target protein such that an 
antibody raised against the peptide forms a specific immune 
complex with the target protein. Preferably, the antigenic 
35 peptide comprises at least 10 amino acid residues, more 
preferably at least 15 amino acid residues, even more 
preferably at least 20 amino acid residues, and most pref-
erably at least 30 amino acid residues. 
III. Recombinant Expression Vectors and Host Cells 
Another aspect of the subject technology pertains to 
vectors, preferably expression vectors, containing a nucleic 
acid encoding a target protein, i.e., a Ca2 + release-stabilizing 
molecule, e.g., Fkbp1a, Fkbp1b variant_a, Fkbp1b vari-
ant_b, Junctophilin 3, Junctophilin 4 and Calmodulin 3 and 
set of potential target protein sequences is expressible as 
individual polypeptides, or alternatively, as a set of larger 40 
fusion proteins (e.g., for phage display) containing the set of 
target protein sequences therein. There are a variety of 
methods which can be used to produce libraries of potential 
target protein variants from a degenerate oligonucleotide 
sequence. Chemical synthesis of a degenerate gene sequence 
can be performed in an automatic DNA synthesizer, and the 
synthetic gene then ligated into an appropriate expression 
vector. Use of a degenerate set of genes allows for the 
provision, in one mixture, of all of the sequences encoding 
the desired set of potential target protein sequences. Meth-
ods for synthesizing degenerate oligonucleotides are known 
45 biologically or functionally active portions thereof, of the 
subject technology. As used herein, the term "vector" 
includes a nucleic acid molecule capable of transporting 
another nucleic acid to which it has been linked. One type 
of vector is a "plasmid", which includes a circular double 
50 stranded DNA loop into which additional DNA segments 
can be ligated. Another type of vector is a viral vector, 
wherein additional DNA segments can be ligated into the 
viral genome. Certain vectors are capable of autonomous 
replication in a host cell into which they are introduced (e.g., 
in the art (see, e.g., Narang, S. A. (1983) Tetrahedron 39:3; 
Itakura eta!. (1984) Annu. Rev. Biochem. 53:323; Itakura et 
a!. (1984) Science 198:1056; Ike eta!. (1983) Nucleic Acid 
Res. 11:477). 
In addition, libraries of fragments of a protein coding 
sequence corresponding to a target protein of the subject 
technology can be used to generate a variegated population 
of target protein fragments for screening and subsequent 
selection of variants of a target protein. In one embodiment, 
a library of coding sequence fragments can be generated by 
treating a double stranded PCR fragment of a target protein 
coding sequence with a nuclease under conditions wherein 
nicking occurs only about once per molecule, denaturing the 
double stranded DNA, renaturing the DNA to form double 
stranded DNA which can include sense/antisense pairs from 
different nicked products, removing single stranded portions 
55 bacterial vectors having a bacterial origin of replication and 
episomal mammalian vectors). Other vectors (e.g., non-
episomal mammalian vectors) are integrated into the 
genome of a host cell upon introduction into the host cell, 
and thereby are replicated along with the host genome. 
60 Moreover, certain vectors are capable of directing the 
expression of genes to which they are operatively linked. 
Such vectors are referred to herein as "expression vectors". 
In general, expression vectors of utility in recombinant DNA 
techniques are often in the form of plasmids. In the present 
65 specification, "plasmid" and "vector" can be used inter-
changeably as the plasmid is the most commonly used form 
of vector. However, the subject technology is intended to 
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include such other forms of expression vectors, such as viral 
vectors (e.g. replication defective retroviruses, adenoviruses 
and adena-associated viruses), which serve equivalent func-
tions. 
The recombinant expression vectors of the subject tech-
nology comprise a nucleic acid of the subject technology in 
a form suitable for expression of the nucleic acid in a host 
cell, which means that the recombinant expression vectors 
include one or more regulatory sequences, selected on the 
basis of the host cells to be used for expression, which is 
operatively linked to the nucleic acid sequence to be 
expressed. Within a recombinant expression vector, "oper-
ably linked" is intended to mean that the nucleotide 
sequence of interest is linked to the regulatory sequence(s) 
in a manner which allows for expression of the nucleotide 
sequence (e.g., in an in vitro transcription/translation system 
or in a host cell when the vector is introduced into the host 
cell). The term "regulatory sequence" is intended to include 
promoters, enhancers and other expression control elements 
(e.g., polyadenylation signals). Such regulatory sequences 
are described, for example, in Goedde!; Gene Expression 
Technology: Methods in Enzymology 185, Academic Press, 
San Diego, Calif. (1990). Regulatory sequences include 
those which direct constitutive expression of a nucleotide 
sequence in many types of host cells and those which direct 
expression of the nucleotide sequence only in certain host 
cells (e.g., tissue-specific regulatory sequences). It will be 
appreciated by those skilled in the art that the design of the 
expression vector can depend on such factors as the choice 
of the host cell to be transformed, the level of expression of 
protein desired, and the like. The expression vectors of the 
subject technology can be introduced into host cells to 
thereby produce proteins or peptides, including fusion pro-
teins or peptides, encoded by nucleic acids as described 
herein (e.g., target proteins, mutant forms of target proteins, 
fusion proteins, and the like). 
The recombinant expression vectors of the subject tech-
nology can be designed for expression of target proteins in 
prokaryotic or eukaryotic cells. For example, target proteins 
can be expressed in bacterial cells such as E. coli, insect cells 
(using baculovirus expression vectors) yeast cells or mam-
malian cells. Suitable host cells are discussed further in 
Goedde!, Gene Expression Technology: Methods in Enzy-
mology 185, Academic Press, San Diego, Calif. (1990). 
Alternatively, the recombinant expression vector can be 
transcribed and translated in vitro, for example using T7 
promoter regulatory sequences and T7 polymerase. 
Expression of proteins in prokaryotes is most often car-
ried out in E. coli with vectors containing constitutive or 
inducible promoters directing the expression of either fusion 
or non-fusion proteins. Fusion vectors add a number of 
amino acids to a protein encoded therein, usually to the 
amino terminus of the recombinant protein. Such fusion 
vectors typically serve three purposes: 1) to increase expres-
sion of recombinant protein; 2) to increase the solubility of 
the recombinant protein; and 3) to aid in the purification of 
the recombinant protein by acting as a ligand in affinity 
purification. Often, in fusion expression vectors, a pro-
teolytic cleavage site is introduced at the junction of the 
fusion moiety and the recombinant protein to enable sepa-
ration of the recombinant protein from the fusion moiety 
subsequent to purification of the fusion protein. Such 
enzymes, and their cognate recognition sequences, include 
Factor Xa, thrombin and enterokinase. Typical fusion 
expression vectors include pGEX (Pharmacia Biotech Inc; 
Smith, D. B. and Johnson, K. S. (1988) Gene 67:31-40), 
pMAL (New England Biolabs, Beverly, Mass.) and pRITS 
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(Pharmacia, Piscataway, N.J.) which fuse glutathione 
S-transferase (GST), maltose E binding protein, or protein 
A, respectively, to the target recombinant protein. 
Purified fusion proteins can be utilized in target activity 
assays, (e.g., direct assays or competitive assays described in 
detail below), or to generate antibodies specific for target 
proteins, for example. 
Examples of suitable inducible non-fusion E. coli expres-
sion vectors include pTrc (Amann et a!., (1988) Gene 
10 69:301-315) and pET 11d (Studier eta!., Gene Expression 
Technology: Methods in Enzymology 185, Academic Press, 
San Diego, Calif. (1990) 60-89). Target gene expression 
from the pTrc vector relies on host RNA polymerase tran-
scription from a hybrid trp-lac fusion promoter. Target gene 
15 expression from the pET 11d vector relies on transcription 
from a T7 gn10-lac fusion promoter mediated by a coex-
pressed viral RNA polymerase (T7 gn1). This viral poly-
merase is supplied by host strains BL21(DE3) or HMS174 
(DE3) from a resident prophage harboring a T7 gn1 gene 
20 under the transcriptional control of the lacUV 5 promoter. 
One strategy to maximize recombinant protein expression 
in E. coli is to express the protein in a host bacteria with an 
impaired capacity to proteolytically cleave the recombinant 
protein (Gottesman, S., Gene Expression Technology: Meth-
25 ods in Enzymology 185, Academic Press, San Diego, Calif. 
(1990) 119-128). Another strategy is to alter the nucleic acid 
sequence of the nucleic acid to be inserted into an expression 
vector so that the individual codons for each amino acid are 
those preferentially utilized in E. coli (Wada eta!., (1992) 
30 Nucleic Acids Res. 20:2111-2118). Such alteration of 
nucleic acid sequences of the subject technology can be 
carried out by standard DNA synthesis techniques. 
In another embodiment, the target protein expression 
vector is a yeast expression vector. Examples of vectors for 
35 expression in yeastS. cerevisiae include p Yep Sec 1 (Baldari, 
et a!., (1987) Embo J. 6:229-234), pMFa (Kmjan and 
Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et 
a!., (1987) Gene 54:113-123), pYES2 (Invitrogen Corpora-
tion, San Diego, Calif.), and picZ (InVitrogen Corp, San 
40 Diego, Calif.). 
Alternatively, target proteins of the subject technology 
can be expressed in insect cells using baculovirus expression 
vectors. Baculovirus vectors available for expression of 
proteins in cultured insect cells (e.g., Sf 9 cells) include the 
45 pAc series (Smith et a!. (1983) Mol. Cell. Bioi. 3:2156-
2165) and the pVL series (Lucklow and Summers (1989) 
Virology 170:31-39). 
In yet another embodiment, a nucleic acid of the subject 
technology is expressed in mammalian cells using a mam-
50 malian expression vector. Examples of mammalian expres-
sion vectors include pCDM8 (Seed, B. (1987) Nature 329: 
840) and pMT2PC (Kaufman eta!. (1987) EMBO J. 6:187-
195). When used in mammalian cells, the expression 
vector's control functions are often provided by viral regu-
55 latory elements. For example, commonly used promoters are 
derived from polyoma, Adenovirus 2, cytomegalovirus and 
Simian Virus 40. For other suitable expression systems for 
both prokaryotic and eukaryotic cells see chapters 16 and 17 
of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular 
60 Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Har-
bor Laboratory, Cold Spring Harbor Laboratory Press, Cold 
Spring Harbor, N.Y., 1989. 
In another embodiment, the recombinant mmalian 
expression vector is capable of directing expression of the 
65 nucleic acid preferentially in a particular cell type (e.g., 
tissue-specific regulatory elements are used to express the 
nucleic acid). Tissue-specific regulatory elements are known 
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A host cell of the subject technology, such as a prokary-
otic or eukaryotic host cell in culture, can be used to produce 
(i.e., express) a target protein. Accordingly, the subject 
technology further provides methods for producing a target 
protein using the host cells of the subject technology. In one 
embodiment, the method comprises culturing the host cell of 
subject technology (into which a recombinant expression 
vector encoding a target protein has been introduced) in a 
suitable medium such that a target protein of the subject 
in the art. Non-limiting examples of suitable tissue-specific 
promoters include the albumin promoter (liver-specific; 
Pinkert et a!. (1987) Genes Dev. 1:268-277), lymphoid-
specific promoters (Calame and Eaton (1988) Adv. Immu-
nol. 43:235-275), in particular promoters ofT cell receptors 
(Winoto and Baltimore (1989) EMBO J. 8:729-733) and 
immunoglobulins (Banerji et a!. (1983) Cell 33:729-740; 
Queen and Baltimore (1983) Cell 33:741-748), neuron-
specific promoters (e.g., the neurofilament promoter; Byrne 
and Ruddle (1989) Proc. Nat!. Acad. Sci. USA 86:5473-
5477), pancreas-specific promoters (Edlund et a!. (1985) 
Science 230:912-916), and mammary gland-specific pro-
moters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 
and European Application Publication No. 264,166). Devel-
opmentally-regulated promoters are also encompassed, for 
example the murine hox promoters (Kessel and Gruss 
(1990) Science 249:374-379) and the fetoprotein promoter 
(Campes and Tilghman (1989) Genes Dev. 3:537-546). 
10 technology is produced. In another embodiment, the method 
further comprises isolating a target protein from the medium 
or the host cell. The host cells of the subject technology can 
also be used to produce non-human transgenic animals. For 
example, in one embodiment, a host cell of the subject 
15 technology is a fertilized oocyte or an embryonic stem cell 
into which target-protein-coding sequences have been intro-
duced. Such host cells can then be used to create non-human 
transgenic animals in which exogenous sequences encoding 
Another aspect of the subject technology pertains to host 
cells into which a nucleic acid molecule of the subject 20 
technology is introduced, e.g., genes of the Ca2 + release-
stabilizing molecules, e.g., FKBP1 b gene within a recom-
binant expression vector or a nucleic acid molecule of the 
subject technology containing sequences which allow it to 
homologously recombine into a specific site of the host 25 
cell's genome. The terms "host cell" and "recombinant host 
cell" are used interchangeably herein. It is understood that 
such terms refer not only to the particular subject cell but to 
the progeny or potential progeny of such a cell. Because 
certain modifications may occur in succeeding generations 30 
due to either mutation or environmental influences, such 
progeny may not, in fact, be identical to the parent cell, but 
are still included within the scope of the term as used herein. 
A host cell can be any prokaryotic or eukaryotic cell. For 
example, a target protein of the subject technology can be 35 
expressed in bacterial cells such as E. coli, insect cells, yeast 
or mammalian cells (such as Chinese hamster ovary cells 
(CHO) or COS cells). Other suitable host cells are known to 
those skilled in the art. 
Vector DNA can be introduced into prokaryotic or eukary- 40 
otic cells via conventional transformation or transfection 
techniques. As used herein, the terms "transformation" and 
"transfection" are intended to refer to a variety of art-
recognized techniques for introducing foreign nucleic acid 
(e.g., DNA) into a host cell, including calcium phosphate or 45 
calcium chloride co-precipitation, DEAE-dextran-mediated 
transfection, lipofection, or electroporation. Suitable meth-
ods for transforming or transfecting host cells can be found 
in Sambrook, et a!. (Molecular Cloning: A Laboratory 
Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold 50 
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 
1989), and other laboratory manuals. 
For stable transfection of mammalian cells, it is known 
that, depending upon the expression vector and transfection 
technique used, only a small fraction of cells may integrate 55 
the foreign DNA into their genome. In order to identifY and 
select these integrants, a gene that encodes a selectable 
target (e.g., resistance to antibiotics) is generally introduced 
into the host cells along with the gene of interest. Preferred 
selectable targets include those which confer resistance to 60 
drugs, such as G418, hygromycin and methotrexate. Nucleic 
acid encoding a selectable target can be introduced into a 
host cell on the same vector as that encoding a target protein 
or can be introduced on a separate vector. Cells stably 
transfected with the introduced nucleic acid can be identified 65 
by drug selection (e.g., cells that have incorporated the 
selectable target gene will survive, while the other cells die). 
a target protein of the subject technology have been intro-
duced into their genome or homologous recombinant ani-
mals in which endogenous sequences encoding the target 
proteins of the subject technology have been altered. Such 
animals are useful for studying the function and/or activity 
of a target protein and for identifying and/or evaluating 
modulators of target protein activity. As used herein, a 
"transgenic animal" is a non-human animal, preferably a 
mammal, more preferably a rodent such as a rat or mouse, 
in which one or more of the cells of the animal includes a 
transgene. Other examples of transgenic animals include 
non-human primates, sheep, dogs, cows, goats, chickens, 
amphibians, and the like. A transgene is exogenous DNA 
which is integrated into the genome of a cell from which a 
transgenic animal develops and which remains in the 
genome of the mature animal, thereby directing the expres-
sion of an encoded gene product in one or more cell types 
or tissues of the transgenic animal. As used herein, a 
"homologous recombinant animal" is a non-human animal, 
preferably a mmal, more preferably a mouse, in which an 
endogenous FKBP1b gene has been altered by homologous 
recombination between the endogenous gene and an exog-
enous DNA molecule introduced into a cell of the animal, 
e.g., an embryonic cell of the animal, prior to development 
of the animal. 
A transgenic animal of the subject technology can be 
created by introducing a target-encoding nucleic acid into 
the male pronuclei of a fertilized oocyte, e.g., by microin-
jection, retroviral infection, and allowing the oocyte to 
develop in a pseudopregnant female foster animal. Intronic 
sequences and polyadenylation signals can also be included 
in the transgene to increase the efficiency of expression of 
the transgene. A tissue-specific regulatory sequence(s) can 
be operably linked to a transgene to direct expression of a 
target protein to particular cells. Methods for generating 
transgenic animals via embryo manipulation and microin-
jection, particularly animals such as mice, have become 
conventional in the art and are described, for example, in 
U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Lederet a!., 
U.S. Pat. No. 4,873,191 by Wagner eta!. and in Hogan, B., 
Manipulating the Mouse Embryo, (Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar 
methods are used for production of other transgenic animals. 
A transgenic founder animal can be identified based upon 
the presence of a trans gene of the subject technology in its 
genome and/or expression of mRNA corresponding to a 
gene of the subject technology in tissues or cells of the 
animals. A transgenic founder animal can then be used to 
breed additional animals carrying the transgene. Moreover, 
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transgenic animals carrying a transgene encoding a target 
protein can further be bred to other transgenic animals 
carrying other transgenes. 
IV. Pharmaceutical Compositions 
The molecules of the subject technology i.e. the Ca2+ 
release-stabilizing molecules (including polypeptides, poly-
nucleotides, small molecules or large molecules that can 
bind to and enhance the activity or stability of the proteins 
of the subject technology (including Fkbp1a, Fkbp1b vari-
ant_a, Fkbp1b variant_b, Junctophilin 3, Junctophilin 4 and 
Calmodulin 3, ryanodine receptors (RyRs), inosital triphos-
phate receptors (InsP3Rs)) can be incorporated into phar-
maceutical compositions suitable for administration. Such 
compositions typically comprise the nucleic acid molecule, 
protein, or small molecules and a pharmaceutically accept-
able carrier. As used herein the language "pharmaceutically 
acceptable carrier" is intended to include any and all sol-
vents, dispersion media, coatings, antibacterial and antifun-
gal agents, isotonic and absorption delaying agents, and the 
like, compatible with pharmaceutical administration. The 
use of such media and agents for pharmaceutically active 
substances is well known in the art. Except insofar as any 
conventional media or agent is incompatible with the active 
compound, use thereof in the compositions is contemplated. 
Supplementary active compounds can also be incorporated 
into the compositions. 
The subject technology includes methods for preparing 
pharmaceutical compositions for modulating the expression 
or activity of a ryanodine receptor (RyR), inosital triphos-
phate receptor (InsP3R) or a polypeptide or nucleic acid 
corresponding to a Ca2+ release-stabilizing molecule of the 
subject technology. Such methods comprise formulating a 
pharmaceutically acceptable carrier with an agent which 
modulates expression or activity of a polypeptide or nucleic 
acid corresponding to a target of the subject technology. 
Such compositions can further include additional active 
agents. Thus, the subject technology further includes meth-
ods for preparing a pharmaceutical composition by formu-
lating a pharmaceutically acceptable carrier with an agent 
which modulates expression or activity of a polypeptide or 
nucleic acid corresponding to a target of the subject tech-
nology and one or more additional active compounds. 
V. Drug Screening Assays 
28 
interactions of the target with one or more of its natural 
substrates (e.g., peptide, protein, hormone, co-factor, or 
nucleic acid), or (d) have a modulatory effect on the expres-
sion of the target. Such assays typically comprise a reaction 
between the target and one or more assay components. The 
other components may be either the test compound itself, or 
a combination of test compound and a natural binding 
partner of the target. 
The test compounds of the present subject technology 
10 
may be obtained from any available source, including sys-
tematic libraries of natural and/or synthetic compounds. Test 
compounds may also be obtained by any of the numerous 
approaches in combinatorial library methods known in the 
art, including: biological libraries; peptoid libraries (libraries 
15 
of molecules having the functionalities of peptides, but with 
a novel, non-peptide backbone which are resistant to enzy-
matic degradation but which nevertheless remain bioactive; 
see, e.g., Zuckermarm eta!., 1994, J. Med. Chern. 37:2678-
85); spatially addressable parallel solid phase or solution 
20 phase libraries; synthetic library methods requiring decon-
volution; the 'one-bead one-compound' library method; and 
synthetic library methods using affinity chromatography 
selection. The biological library and peptoid library 
approaches are limited to peptide libraries, while the other 
25 four approaches are applicable to peptide, non-peptide oli-
gomer or small molecule libraries of compounds (Lam, 
1997, Anticancer Drug Des. 12:145). 
In one exemplary assay format, the ability of a molecule 
to modulate the expression and/or the function of a gene or 
30 protein of the subject technology is assayed by monitoring 
the expression and/or function of said gene or protein in cell 
lines which were exposed to the molecule and comparing 
said expression to that in cell lines which were not exposed 
to the molecule. Such monitoring can be done using standard 
35 procedures such those disclosed in Sambrook eta!., (1989) 
Molecular Cloning-A Laboratory Manual, Cold Spring 
Harbor Laboratory Press). 
Molecules that are assayed in the above methods can be 
randomly selected or rationally selected or designed. As 
40 
used herein, a molecule is said to be randomly selected when 
the molecule is chosen randomly without considering the 
specific sequences involved in the association of the a 
protein of the subject technology alone or with its associated 
substrates, binding partners, etc. An example of randomly 
45 
selected molecules is the use a chemical library or a peptide 
combinatorial library, or a growth broth of an organism. 
VI. Routes of Administration 
The subject technology also provides methods (also 
referred to herein as "screening assays") for identifying 
modulators, i.e., candidate or test compounds or agents (e.g. 
peptides, peptidomimetics, peptoids, small molecules or 
large molecules or other drugs) which (a) bind to the target 
(i.e., FKBP1a, FKBP1 b, junctophilin 3, junctophilin 4, 
calmodulin 3, RyRs, InsP3Rs, a variant thereof or a func- 50 
tiona! fragment thereof), or (b) have a modulatory (e.g., 
stimulatory or inhibitory) effect on the activity of the target 
A pharmaceutical composition or polypeptide, polynucle-
otide, small molecule or large molecule of the subject 
technology is formulated to be compatible with its intended 
route of administration. Examples of routes of administra-
tion and dosage forms of such formulations are shown in the 
Table below. or, more specifically, (c) have a modulatory effect on the 
Routes of administration/Dosage forms 
Oral Digestive tract Solids Pill, Tablet, Capsule, Time release technology, 
(enteral) Osmotic controlled release capsule (OROS) 
Liquids Solution, Softgel, Suspension, Emulsion, 
Syrup, Elixir, Tincture, Hydrogel 
Buccal/ Solids Orally Disintegrating Tablet (ODT), Film, 
Sub labial/ Lollipop, Lozenges, Chewing gum 
Sublingual Liquids Mouthwash, Toothpaste, Ointment, Oral spray 
Respiratory Solids Smoking device Dry Powder Inhaler (DPI) 
tract Liquids pressurized Metered Dose Inhaler (pMDI), 
Nebulizer, Vaporizer 
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-continued 
Routes of administration/Dosage forms 
Gas Oxygen mask, Oxygen concentrator, 
Anaesthetic machine, Relative analgesia 
machine 
Ophthalmic/ 
Otologic/ 
Nasal 
Urogenital 
Nasal spray, Ear drops, Eye drops, Ointment, Hydrogel, Nanosphere 
suspension, Mucoadhesive microdisc (microsphere tablet) 
Rectal 
(enteral) 
Dermal 
Ointment, Pessary (vaginal suppository), Vaginal ring, Vaginal douche, 
Intrauterine device (IUD), Extra-anmiotic infusion, Intravesical infusion 
Ointment, Suppository, Enema (Solution, Hydrogel), Murphy drip, Nutrient 
enema 
Ointment, Liniment, Paste, Film, Hydrogel, Liposomes, Transfersome 
vesicles, Cream, Lotion, Lip balm, Medicated shampoo, Dermal patch, 
Transdermal patch, Transdermal spray, Jet injector 
Injection/ 
Infusion 
(into 
tissue/blood) 
Skin Intradermal, Subcutaneous, Transdermal implant 
Organs Intracavernous, Intravitreal, Intra-articular, or 
intrasynovial injection, Transscleral 
Central nervous Intracerebral, Intrathecal, Epidural 
system 
Circulatory/ 
Musculoskeletal 
Intravenous, Intracardiac, Intramuscular, Intraosseous, 
Intraperitoneal, Nanocell injection 
Alternative or additional examples of routes of adminis-
tration include parenteral, e,g,, intravenous, intradermal, 
subcutaneous, oral ( e,g,, inhalation), transdermal (topical), 
transmucosal, and rectal administration, Solutions or sus-
pensions used for parenteral, intradermal, or subcutaneous 
application can include the following components: a sterile 
diluent such as water for injection, saline solution, fixed oils, 
polyethylene glycols, glycerine, propylene glycol or other 
synthetic solvents; antibacterial agents such as benzyl alco-
hol or methyl parabens; antioxidants such as ascorbic acid or 
sodium bisulfite; chelating agents such as ethylenedi-
aminetetraacetic acid; buffers such as acetates, citrates or 
phosphates and agents for the adjustment of tonicity such as 
sodium chloride or dextrose, pH can be adjusted with acids 
brought about by including in the compositiOn an agent 
which delays absorption, for example, aluminum monoste-
25 arate and gelatin, 
Sterile injectable solutions can be prepared by incorpo-
rating the active compound ( e,g,, a fragment of a target 
protein) in the required amount in an appropriate solvent 
with one or a combination of ingredients enumerated above, 
30 as required, followed by filtered sterilization, Generally, 
dispersions are prepared by incorporating the active com-
pound into a sterile vehicle which contains a basic disper-
sion medium and the required other ingredients from those 
enumerated above, In the case of sterile powders for the 
35 preparation of sterile injectable solutions, the preferred 
methods of preparation are vacuum drying and freeze-drying 
which yields a powder of the active ingredient plus any 
additional desired ingredient from a previously sterile-fil-or bases, such as hydrochloric acid or sodium hydroxide, 
The parenteral preparation can be enclosed in ampoules, 
disposable syringes or multiple dose vials made of glass or 40 
plastic, 
Pharmaceutical compositions suitable for injectable use 
include sterile aqueous solutions (where water soluble) or 
dispersions and sterile powders for the extemporaneous 
preparation of sterile injectable solutions or dispersion, For 45 
intravenous administration, suitable carriers include physi-
ological saline, bacteriostatic water, Cremophor EL™ 
(BASF, Parsippany, N,J,) or phosphate buffered saline 
(PBS), In all cases, the composition must be sterile and 
should be fluid to the extent that easy syringability exists, It 50 
must be stable under the conditions of manufacture and 
tered solution thereof 
Oral compositions generally include an inert diluent or an 
edible carrier, They can be enclosed in gelatin capsules or 
compressed into tablets, For the purpose of oral therapeutic 
administration, the active compound can be incorporated 
with excipients and used in the form of tablets, troches, or 
capsules, oral compositions can also be prepared using a 
fluid carrier for use as a mouthwash, wherein the compound 
in the fluid carrier is applied orally and swished and expec-
torated or swallowed, Pharmaceutically compatible binding 
agents, and/or adjuvant materials can be included as part of 
the composition, The tablets, pills, capsules, troches and the 
like can contain any of the following ingredients, or com-
pounds of a similar nature: a binder such as microcrystalline 
cellulose, gum tragacanth or gelatin; an excipient such as 
starch or lactose, a disintegrating agent such as alginic acid, 
storage and must be preserved against the contaminating 
action of microorganisms such as bacteria and fungi, The 
carrier can be a solvent or dispersion medium containing, for 
example, water, ethanol, polyol (for example, glycerol, 
propylene glycol, and liquid polyetheylene glycol, and the 
like), and suitable mixtures thereof The proper fluidity can 
55 Primage!, or corn starch; a lubricant such as magnesium 
stearate or Sterotes; a glidant such as colloidal silicon 
dioxide; a sweetening agent such as sucrose or saccharin; or 
a flavoring agent such as peppermint, methyl salicylate, or be maintained, for example, by the use of a coating such as 
lecithin, by the maintenance of the required particle size in 
the case of dispersion and by the use of surfactants, Pre- 60 
vention of the action of microorganisms can be achieved by 
various antibacterial and antifingal agents, for example, 
parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, 
and the like, In many cases, it will be preferable to include 
isotonic agents, for example, sugars, polyalcohols such as 
manito!, sorbitol, sodium chloride in the composition, Pro-
longed absorption of the injectable compositions can be 
orange flavoring, 
For administration by inhalation, the compounds are 
delivered in the form of an aerosol spray from pressured 
container or dispenser which contains a suitable propellant, 
e,g,, a gas such as carbon dioxide, or a nebulizer, 
Systemic administration can also be by transmucosal or 
65 transdermal means, For transmucosal or transdermal admin-
istration, penetrants appropriate to the barrier to be perme-
ated are used in the formulation, Such penetrants are gen-
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erally known in the art, and include, for example, for 
transmucosal administration, detergents, bile salts, and 
fusidic acid derivatives. Transmucosal administration can be 
accomplished through the use of nasal sprays or supposito-
ries. For transdermal administration, the active compounds 
are formulated into ointments, salves, gels, or creams as 
generally known in the art. 
32 
pound which achieves a half-maximal inhibition of symp-
toms) as determined in cell culture. Such information can be 
used to more accurately determine useful doses in humans. 
Levels in plasma may be measured, for example, by high 
performance liquid chromatography. 
The nucleic acid molecules of the subject technology can 
be inserted into vectors and used as gene therapy vectors. 
Gene therapy vectors can be delivered to a subject by, for 
example, intravenous injection, local administration (see 
The compounds can also be prepared in the form of 
suppositories (e.g., with conventional suppository bases 
such as cocoa butter and other glycerides) or retention 
enemas for rectal delivery. 
10 U.S. Pat. No. 5,328,470) or by stereotactic injection (see 
e.g., Chen eta!. (1994) Proc. Nat!. Acad. Sci. USA 91:3054-
3057). The pharmaceutical preparation of the gene therapy 
vector can include the gene therapy vector in an acceptable 
diluent, or can comprise a slow release matrix in which the 
In one embodiment, the active compounds are prepared 
with carriers that will protect the compound against rapid 
elimination from the body, such as a controlled release 
formulation, including implants and microencapsulated 
delivery systems. Biodegradable, biocompatible polymers 
can be used, such as ethylene vinyl acetate, polyanhydrides, 
polyglycolic acid, collagen, polyorthoesters, and polylactic 
acid. Methods for preparation of such formulations will be 
apparent to those skilled in the art. The materials can also be 20 
obtained commercially from Alza Corporation and Nova 
Pharmaceuticals, Inc. Liposomal suspensions (including 
liposomes targeted to infected cells with monoclonal anti-
bodies to viral antigens) can also be used as pharmaceuti-
cally acceptable carriers. These can be prepared according to 25 
methods known to those skilled in the art, for example, as 
described in U.S. Pat. No. 4,522,811. 
15 gene delivery vehicle is imbedded. Alternatively, where the 
complete gene delivery vector can be produced intact from 
recombinant cells, e.g., retroviral vectors, the pharmaceuti-
cal preparation can include one or more cells which produce 
It is especially advantageous to formulate oral or paren-
teral compositions in dosage unit form for ease of admin-
istration and uniformity of dosage. Dosage unit form as used 30 
herein includes physically discrete units suited as unitary 
dosages for the subject to be treated; each unit containing a 
predetermined quantity of active compound calculated to 
produce the desired therapeutic effect in association with the 
required pharmaceutical carrier. The specification for the 35 
dosage unit forms of the subject technology are dictated by 
and directly dependent on the unique characteristics of the 
active compound and the particular therapeutic effect to be 
achieved, and the limitations inherent in the art of com-
pounding such an active compound for the treatment of 40 
individuals. 
Toxicity and therapeutic efficacy of the molecules of the 
subject technology can be determined by standard pharma-
ceutical procedures in cell cultures or experimental animals, 
e.g., for determining the LD50 (the dose lethal to 50% of the 45 
population) and the ED50 (the dose therapeutically effective 
in 50% of the population). The dose ratio between toxic and 
therapeutic effects is the therapeutic index and it can be 
expressed as the ratio LD50/ED50. Compounds which 
exhibit large therapeutic indices are preferred. While com- 50 
pounds that exhibit toxic side effects may be used, care 
should be taken to design a delivery system that targets such 
compounds to the site of affected tissue in order to minimize 
potential damage to uninfected cells and, thereby, reduce 
side effects. 55 
The data obtained from the cell culture assays and animal 
studies can be used in formulating a range of dosage for use 
the gene delivery system. 
The pharmaceutical compositions can be included in a 
container, pack, or dispenser together with instructions for 
administration. 
VI. Methods of Treatment 
The subject technology provides for both prophylactic 
and therapeutic methods of treating Alzheimer's Disease 
(AD), early-stage AD, elevated risk of AD, mild cognitive 
impairment (MCI), or other forms of age-related cognitive 
decline in a subject. In some embodiments, the subject 
technology provides a method of treating Alzheimer's Dis-
ease (AD), early-stage AD, elevated risk of AD, mild 
cognitive impairment (MCI), or other forms of age-related 
cognitive decline in a subject in need thereof, comprising 
administering to the subject a molecule that promotes cal-
cium-release stabilization in ryanodine receptors (RyR) and/ 
or inosital triphosphate receptors (InsP3R) in brain cells. 
In some other embodiments, the subject technology pro-
vides a method of treating Alzheimer's Disease (AD), early-
stage AD, elevated risk of AD, mild cognitive impairment 
(MCI), or other forms of age-related cognitive decline in a 
subject in need thereof, comprising administering to the 
subject a calcium (Ca2+)-release stabilizing molecule, 
wherein said molecule induces reduction, inhibition or 
reversal of Ca2+ dysregulation in brain cells of the subject. 
In an embodiment, the subject technology also provides 
methods of preventing the development AD or other cog-
nitive impairments associated with Ca2 + dysregulation in a 
subject. These methods involve, for targets that are signifi-
cantly decreased in expression or activity, the administration 
of that target protein, or the introduction of mRNA or DNA 
corresponding to the decreased target (e.g., by gene 
therapy), to thereby increase the levels of the target protein 
in the subject. In this manner, the development AD or other 
cognitive impairments associated with Ca2 + dysregulation in 
a subject can be prevented. 
With regards to both prophylactic and therapeutic meth-
ods of treatment, such treatments may be specifically tai-
lored or modified, based on knowledge obtained from the 
field of pharmacogenomics. "Pharmacogenomics", as used 
herein, includes the application of genomics technologies 
in humans. The dosage of such compounds lies preferably 
within a range of circulating concentrations that include the 
ED 50 with little or no toxicity. The dosage may vary within 
this range depending upon the dosage form employed and 
the route of administration utilized. For any compound used 
in the method of the subject technology, the therapeutically 
effective dose can be estimated initially from cell culture 
assays. A dose may be formulated in animal models to 
achieve a circulating plasma concentration range that 
includes the IC50 (i.e., the concentration of the test com-
60 such as gene sequencing, statistical genetics, and gene 
expression analysis to drugs in clinical development and on 
the market. More specifically, the term refers the study of 
how a subject's genes determine his or her response to a 
drug (e.g., a subject's "drug response phenotype", or "drug 
65 response genotype".) Thus, another aspect of the subject 
technology provides methods for tailoring an individual's 
prophylactic or therapeutic treatment with either the target 
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molecules of the present subject technology or target modu-
lators according to that individual's drug response genotype. 
Pharmacogenomics allows a clinician or physician to target 
prophylactic or therapeutic treatments to subjects who will 
most benefit from the treatment and to avoid treatment of 
subjects who will experience toxic drug-related side effects. 
In one aspect, the subject technology provides a method 
for preventing in a subject, a disease or condition (e.g., AD 
34 
Another aspect of the subject technology pertains to 
methods of modulating the expression or activity of a target 
protein (i.e., a Ca2+ release-stabilizing molecule or a Ca2+ 
receptor of the subject technology) for therapeutic purposes. 
Accordingly, in an exemplary embodiment, the modulatory 
method of the subject technology involves contacting a cell 
with a molecule or agent that modulates the expression or 
activity of a target protein. A molecule or an agent that 
modulates the expression or activity of a target protein can 
or other cognitive impairments) associated with decreased 
target expression or activity or associated with aberrant 
target activity (e.g., calcium release dysregulation in RyRs 
and/or InsP3Rs), by administering to the subject a molecule 
or an agent which modulates target protein expression or at 
least one target protein activity in a way that the course of 
the Ca2 + -dysregulation associated with aging and/or AD 
phenotype is stopped or reversed. Subjects at risk for a 
disease which is caused or contributed to by decreased target 
expression or activity can be identified by, for example, any 
10 be a nucleic acid or a protein, a naturally-occurring target 
molecule of a target protein (e.g., a target protein substrate), 
a target protein antibody, a target protein agonist or antago-
nist, a peptidomimetic of a target protein agonist or antago-
nist, or other small or large molecules. In one embodiment, 
15 the molecule stimulates one or more target protein. 
or a combination of diagnostic or prognostic assays as 20 
described herein. Administration of a prophylactic agent can 
occur prior to the manifestation of symptoms characteristic 
of the differential target protein expression, such that a 
disease or disorder is prevented or, alternatively, delayed in 
its progression. Depending on the type of target aberrancy 25 
(e.g., increase or decrease in expression level), for example, 
a target protein, target protein agonist or target protein 
antagonist agent can be used for treating the subject. The 
appropriate agent can be determined based on screening 
assays described herein. Examples of agents such as small 30 
molecules or large molecules that modulate the target mol-
ecules (e.g., Ca2 + release-stabilizing molecules or Ca2+ 
channels including RyRs and InsP3Rs) of the subject tech-
nology can be immunosuppressants such as rapamycin, and 
analogues of rapamycin, such as CCI-779 and analogue 35 
described in U.S. Pat. No. 5,362,718, incorporated herein by 
reference, FK506, macolides of FK506 and rapamycin (Du-
mont, F. et a!., "The Immunosuppressive Macrolides 
FK-506 and Rapamycin Act as Reciprocal Antagonists in 
Murine T Cells", J. Immunol. 144: 1418-1424 (1990), 40 
synthetic anmalogues ofrapamycin, FK506 (R. S. Coleman 
et a!., "Degradation and Manipulations of the Immunosup-
pressant FK506: Preparation of Potential Synthetic Interme-
diates," Heterocycles, 28, pp. 157-161 (1989) and U.S. Pat. 
No. 6,200,985, each of which is hereby incorporated herein 45 
by reference) or JTV519 (K201) a 1,4-benzothiazepine drug 
with antiarrhythmic and cardioprotective properties (see 
Diabetes, Metabolic Syndrome and Obesity: Targets and 
Therapy 2012:5 89-99, which is hereby incorporated herein 
Examples of such stimulatory agents include active target 
protein and a nucleic acid molecule encoding target protein 
that has been introduced into the cell. In another embodi-
ment, the molecule inhibits one or more target protein 
activities. Examples of such inhibitory molecules include 
antisense target protein nucleic acid molecules, anti-target 
protein antibodies, and target protein inhibitors. These 
modulatory methods can be performed in vitro (e.g., by 
culturing the cell with the agent) or, alternatively, in vivo 
(e.g., by administering the agent to a subject). As such, the 
present subject technology provides methods of treating an 
individual afflicted with a disease or disorder characterized 
by aberrant expression or activity of a target protein or 
nucleic acid molecule. In one embodiment, the method 
involves administering a molecule or an agent (e.g., an agent 
identified by a screening assay described herein), or com-
bination of agents that modulates (e.g., upregulates or cor-
rects) target protein expression or activity. In another 
embodiment, the method involves administering a target 
protein or nucleic acid molecule as therapy to compensate 
for reduced or aberrant target protein expression or activity. 
Stimulation of target protein activity is desirable in situ-
ations in which target protein is abnormally downregulated 
and/or in which increased target protein activity is likely to 
have a beneficial effect. For example, stimulation of target 
protein activity is desirable in situations in which a target is 
downregulated and/or in which increased target protein 
activity is likely to have a beneficial effect. 
In another embodiment, the subject technology provides 
a method of treating a subject afflicted with AD or other 
cognitive impairments, including providing to cells of the 
subject a protein with Ca2 + release-stabilizing activity, e.g., 
FKBP1 b. In a related embodiment, the protein is provided to 
the cells by providing a vector including a polynucleotide 
by reference). 
Alternatively, the examples of molecules that can be used 
in the methods of the subject technology further include 
non-immunosuppressive ligands. The non-immunosuppres-
sive lingand of immunophilins, junctophilins, calmodulins 
50 encoding the Ca2 + release-stabilizing molecules, e.g., 
FKBP1b protein to the cells. 
or calcium receptors of the subject technology can be a low 55 
molecular weight, small molecule compound having an 
affinity for the Ca2 + release-stabilizing molecules or Ca2+ 
receptors of the subject technology. For example, when the 
compound binds to a Ca2+ release-stabilizing molecule, it 
can enhance its Ca2 + release-stabilizing activity. As its name 60 
suggests, the non-immunosuppressive ligands or com-
pounds are devoid of any significant immunosuppressive 
activity. Examples of a non-immunosuppressive neurolm-
munophilin FKBP ligands that may be used in the method 
and pharmaceutical composition of the subject technology 65 
are set forth, for example, in PCT Publication W000/09108, 
which is hereby incorporated herein by reference. 
In another embodiment, the subject technology provides 
a method of inhibiting AD or other cognitive impairments 
associated with Ca2 + dysregulation in a subject at risk for 
developing AD or other cognitive impairments, including 
stimulating the activity (in case of protein) or expression (in 
case of a gene) of a Ca2+ release-stabilizing molecule, e.g., 
FKBP1b. 
In another embodiment, the subject technology provides 
a method of treating a subject afflicted with AD or other 
cognitive impairments, including providing to cells of the 
subject a molecule (e.g., a polynucleotide, a protein or a 
small organic or large molecule) that can ligate to and 
stabilize Ry receptor, InsP3 receptor, or a Ca2+ release-
stabilizing molecule, e.g., FKBP1 b, in said cells of the 
subject. In a related embodiment, the molecule can enhance 
the activity of the Ca2+ release-stabilizing molecules in vivo. 
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VII. Predictive Medicine 
The present subject technology pertains to the field of 
predictive medicine in which diagnostic assays and prog-
nostic assays are used for prognostic (predictive) purposes to 
thereby treat an individual prophylactically. 
1. Diagnostic Assays 
36 
control sample with the presence of target protein, mRNA or 
genomic DNA in the test sample. 
The subject technology includes methods that quantifY 
expression levels in clinical samples as well as methods that 
determine whether a gene of interest is expressed at all or 
expressed above a threshold (e.g., a control threshold) in 
clinical samples. Thus, an assay which provides a "yes or 
no" result without necessarily providing quantification of 
gene expression is within the scope of the subject technol-
In some embodiments, the subject technology relates to 
diagnostic assays for diagnosing Alzheimer's Disease (AD), 
early-stage AD, elevated risk of AD or mild cognitive 
impairment (MCI) in a patient, including obtaining a bio-
logical sample from the patient, detecting presence, quantity, 
10 ogy. The subject technology may involve quantitative or 
qualitative assessment of gene expression. 
Various methods for detecting the level of expression of 
one or more genes in a sample is known in the art. For 
example, traditional Northern blotting, nuclease protection, 
or level of expression of one or more calcium-release 
stabilizing immunophilin, junctophilin and/or calmodulin 
genes in the biological sample from said patient, wherein a 
difference in the presence, quantity or level of expression of 
said one or more genes in the sample as compared to a 
control is indicative of Alzheimer's Disease (AD), early-
stage AD, elevated risk of AD or mild cognitive impairment 
(MCI). 
15 RT-PCR and differential display methods may be used for 
detecting gene expression levels, including Taqman and flap 
endonuclease assays. Additional assays include array or chip 
hybridization-based methods, which are convenient when 
determining the expression levels of a larger number of 
20 genes. 
An exemplary agent for detecting target protein is an 
antibody capable of binding to target protein, preferably an 
antibody with a detectable label. Antibodies can be poly-
clonal, or more preferably, monoclonal. An intact antibody, 
In some embodiments, the subject technology may 
employ reverse transcription polymerase chain reaction (RT-
PCR), which is a sensitive method for the detection of 
mRNA, including low abundant mRNAs present in clinical 
25 tissue samples. The application of fluorescence techniques 
to RT-PCR combined with suitable instrumentation has led 
or a fragment thereof (eg., Fab or F(ab')2 ) can be used. The 
term "labeled", with regard to the probe or antibody, is 
intended to encompass direct labeling of the probe or 
antibody by coupling (i.e., physically linking) a detectable 
substance to the probe or antibody, as well as indirect 
labeling of the probe or antibody by reactivity with another 30 
reagent that is directly labeled. Examples of indirect labeling 
include detection of a primary antibody using a fluorescently 
labeled secondary antibody and end-labeling of a DNA 
probe with biotin such that it can be detected with fluores-
cently labeled streptavidin. The term "biological sample" is 35 
intended to include tissues, cells and biological fluids iso-
lated from a subject, as well as tissues, cells and fluids 
present within a subject. That is, the detection method of the 
subject technology can be used to detect target mRNA, 
protein, or genomic DNA in a biological sample in vitro as 40 
well as in vivo. For example, in vitro techniques for detec-
tion of target mRNA include Northern hybridizations and in 
situ hybridizations. In vitro techniques for detection of target 
protein include enzyme linked immunosorbent assays (ELI-
SAs), Western blots, immunoprecipitations and immuno- 45 
fluorescence. In vitro techniques for detection of target 
genomic DNA include Southern hybridizations. Further-
more, in vivo techniques for detection of target protein 
include introducing into a subject a labeled anti-target anti-
body. For example, the antibody can be labeled with a 50 
radioactive target whose presence and location in a subject 
can be detected by standard imaging techniques. 
In one embodiment, the biological sample contains pro-
tein molecules from the patient or test subject. Alternatively, 
the biological sample can contain mRNA molecules from 55 
the test subject or genomic DNA molecules from the test 
subject. A preferred biological sample is a serum sample 
isolated by conventional means from a subject. 
In another embodiment, the methods further involve 
obtaining a control biological sample (e.g., non-AD or 60 
samples showing no cognitive impairments associated with 
Ca2+ dysregulation) from a control subject, contacting the 
control sample with a compound or agent capable of detect-
ing target protein, mRNA, or genomic DNA, such that the 
presence of target protein, mRNA or genomic DNA is 65 
detected in the biological sample, and comparing the pres-
ence of target protein, mRNA or genomic DNA in the 
to quantitative RT-PCR methods that combine amplification, 
detection and quantification in a closed system. Two com-
monly used quantitative RT-PCR techniques are the Taqman 
RT-PCR assay (ABI, Foster City, USA) and the Lightcycler 
assay (Roche, USA). 
In other embodiments, the subject technology employs 
detection and quantification of RNA levels in real-time using 
nucleic acid sequence based amplification (NASBA) com-
bined with molecular beacon detection molecules. NASBA 
is a singe-step isothermal RNA-specific amplification 
method that amplifies mRNA in a double stranded DNA 
environment, and this method has recently proven useful in 
the detection of various mRNAs, and in the detection of both 
viral and bacterial RNA in clinical samples. 
In yet other embodiments, the subject technology uses an 
assay employing a flap endonuclease, such as the Invader™ 
assay (Third Wave Technologies). In the case of using the 
invader method, an invader probe containing a sequence 
specific to the region 3' to a target site, and a primary probe 
containing a sequence specific to the region 5' to the target 
site of a template and an unrelated flap sequence, are 
prepared. Cleavase is then allowed to act in the presence of 
these probes, the target molecule, as well as a FRET probe 
containing a sequence complementary to the flap sequence 
and an auto-complementary sequence that is labeled with 
both a fluorescent dye and a quencher. When the primary 
probe hybridizes with the template, the 3' end of the invader 
probe penetrates the target site, and this structure is cleaved 
by the Cleavase resulting in dissociation of the flap. The flap 
binds to the FRET probe and the fluorescent dye portion is 
cleaved by the Cleavase resulting in emission of fluores-
cence. 
In another embodiment, the subject technology employs 
hybridization-based assays. Nucleic acid hybridization sim-
ply involves contacting a probe and target nucleic acid under 
conditions where the probe and its complementary target can 
form stable hybrid duplexes through complementary base 
pairing (see Lockhart et a!., (1999) WO 99/32660). The 
nucleic acids that do not form hybrid duplexes are then 
washed away leaving the hybridized nucleic acids to be 
detected, typically through detection of an attached detect-
US 9,464,322 B2 
37 
able label. It is generally recognized that nucleic acids are 
denatured by increasing the temperature or decreasing the 
salt concentration of the buffer containing the nucleic acids. 
Under low stringency conditions (e.g., low temperature 
and/or high salt) hybrid duplexes (e.g., DNA-DNA, RNA-
RNA or RNA-DNA) will form even where the annealed 
sequences are not perfectly complementary. Thus specificity 
of hybridization is reduced at lower stringency. Conversely, 
at higher stringency (e.g., higher temperature or lower salt) 
successful hybridization requires fewer mismatches. One of 10 
skill in the art will appreciate that hybridization conditions 
may be selected to provide any degree of stringency. In a 
preferred embodiment, hybridization is performed at low 
stringency, in this case in 6xSSPE-T at 37° C. (0.005% 
Triton x-100) to ensure hybridization and then subsequent 15 
washes are performed at higher stringency (e.g., 1xSSPE-T 
at 37° C.) to eliminate mismatched hybrid duplexes. Suc-
cessive washes may be performed at increasingly higher 
stringency (e.g., down to as low as 0.25xSSPET at 37° C. to 
50° C.) until a desired level of hybridization specificity is 20 
obtained. Stringency can also be increased by addition of 
agents such as formamide. Hybridization specificity may be 
evaluated by comparison of hybridization to the test probes 
with hybridization to the various controls that can be present 
(e.g., expression level control, normalization control, mis- 25 
match controls, etc.). 
The hybridized nucleic acids are typically detected by 
detecting one or more labels attached to the sample nucleic 
acids. The labels may be incorporated by any of a number of 
means well known to those of skill in the art (see Lockhart 30 
eta!., (1999) WO 99/32660). 
When employing hybridization formats, solution-based 
and solid support-based assay formats may be employed. 
Solid supports containing oligonucleotide probes for differ-
entially expressed genes of the subject technology can be 35 
filters, polyvinyl chloride dishes, silicon or glass based 
chips, etc. Such wafers and hybridization methods are 
widely available, for example, those disclosed by Beattie 
(WO 95/11755). Any solid surface to which oligonucle-
otides can be bound, either directly or indirectly, either 40 
covalently or non-covalently, can be used. An exemplary 
solid support is a high density array or DNA chip. These 
contain a particular oligonucleotide probe in a predeter-
mined location on the array. Each predetermined location 
may contain more than one molecule of the probe, but each 45 
molecule within the predetermined location has an identical 
sequence. Such predetermined locations are termed features. 
There may be, for example, about 2, 10, 100, 1000 to 
1 0,000; 100,000 or 400,000 of such features on a single solid 
support. The solid support, or the area within which the 50 
probes are attached may be on the order of a square 
centimeter. 
Oligonucleotide probe arrays for expression monitoring 
can be made and used according to any techniques known in 
the art (see for example, Lockhart eta!., (1996) Nat. Bio- 55 
techno!. 14, 1675-1680; McGall et a!., (1996) Proc. Nat. 
Acad. Sci. USA 93, 13555-13460). Such probe arrays may 
contain at least two or more oligonucleotides that are 
complementary to or hybridize to two or more of the genes 
described herein. Such arrays may also contain oligonucle- 60 
otides that are complementary or hybridize to at least about 
2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, or all of the genes 
described herein as being differentially expressed in AD. 
Probes based on the sequences of the genes described 
herein may be prepared by any commonly available method. 65 
Oligonucleotide probes for assaying the tissue or cell sample 
are preferably of sufficient length to specifically hybridize 
38 
only to appropriate, complementary genes or transcripts. 
Typically the oligonucleotide probes will be at least 10, 12, 
14, 16, 18, 20 or 25 nucleotides in length. In some cases 
longer probes of at least 30, 40, or 50 nucleotides will be 
desirable. 
As used herein, oligonucleotide sequences that are 
complementary to one or more of the genes described 
herein, refers to oligonucleotides that are capable of hybrid-
izing under stringent conditions to at least part of the 
nucleotide sequence of said genes. Such hybridizable oli-
gonucleotides will typically exhibit at least about 75% 
sequence identity at the nucleotide level to said genes, 
preferably about 80% or 85% sequence identity or more 
preferably about 90% or 95% or more sequence identity to 
said genes. In some embodiments, the oligonucleotide 
probes are identical to a portion of the genes disclosed 
herein, and usually identical in a range of 10-30 nucleotides, 
such as 15-20 nucleotides. 
Further, with respect to arrays, one of skill in the art will 
appreciate that an enormous number of array designs are 
suitable for the practice of the subject technology, where 
array embodiments are desirable. The array will typically 
include a number of probes that specifically hybridize to the 
sequences of interest. See WO 99/32660 for methods of 
producing probes for a given gene or genes. In addition, in 
a preferred embodiment, the array will include one or more 
control probes. 
High density array chips of the subject technology include 
"test probes." Test probes may be oligonucleotides that 
range from about 5 to about 500 or about 5 to about 50 
nucleotides, more preferably from about 10 to about 40 
nucleotides and most preferably from about 15 to about 40 
nucleotides in length. In other particularly preferred embodi-
ments the probes are about 20 to 25 nucleotides in length. In 
another preferred embodiment, test probes are double or 
single strand DNA sequences. DNA sequences are isolated 
or cloned from natural sources or amplified from natural 
sources using natural nucleic acid as templates. These 
probes have sequences complementary to particular subse-
quences of the genes whose expression they are designed to 
detect. Thus, the test probes are capable of specifically 
hybridizing to the target nucleic acid they are to detect. 
In addition to test probes that bind the target nucleic 
acid(s) of interest, the high density array can contain a 
number of control probes. The control probes fall into three 
categories referred to herein as (1) normalization controls; 
(2) expression level controls; and (3) mismatch controls. 
Normalization controls are oligonucleotide or other 
nucleic acid probes that are complementary to labeled 
reference oligonucleotides or other nucleic acid sequences 
that are added to the nucleic acid sample. The signals 
obtained from the normalization controls after hybridization 
provide a control for variations in hybridization conditions, 
label intensity, "reading" efficiency and other factors that 
may cause the signal of a perfect hybridization to vary 
between arrays. In a preferred embodiment, signals (e.g., 
fluorescence intensity) read from all other probes in the 
array are divided by the signal (e.g., fluorescence intensity) 
from the control probes thereby normalizing the measure-
ments. Other methods for normalizing gene expression data 
are known in the art, such as those described, for example, 
in W02001/020043 or US 20060136145, each of which is 
hereby incorporated herein by reference. 
Virtually any probe may serve as a normalization control. 
However, it is recognized that hybridization efficiency varies 
with base composition and probe length. Preferred normal-
ization probes are selected to reflect the average length of the 
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other probes present in the array, however, they can be 
selected to cover a range of lengths. The normalization 
control( s) can also be selected to reflect the (average) base 
composition of the other probes in the array, however in a 
preferred embodiment, only one or a few probes are used 
and they are selected such that they hybridize well (i.e., no 
secondary structure) and do not match any target -specific 
probes. 
Expression level controls are probes that hybridize spe-
cifically with constitutively expressed genes in the biologi- 10 
cal sample. Virtually any constitutively expressed gene 
provides a suitable target for expression level controls. 
Typical expression level control probes have sequences 
complementary to subsequences of constitutively expressed 
"housekeeping genes" including, but not limited to the 15 
beta-actin gene, the transferrin receptor gene, the GAPDH 
gene, the HPRTl gene, and the like. Alternatively or in 
addition, the expression level controls can be obtained from 
genes whose expressions are known not to change with AD. 
Mismatch controls may also be provided for the probes to 20 
the target genes, for expression level controls or for nor-
malization controls. Mismatch controls are oligonucleotide 
probes or other nucleic acid probes identical to their corre-
sponding test or control probes except for the presence of 
one or more mismatched bases. A mismatched base is a base 25 
selected so that it is not complementary to the corresponding 
base in the target sequence to which the probe would 
otherwise specifically hybridize. One or more mismatches 
are selected such that under appropriate hybridization con-
ditions (e.g., stringent conditions) the test or control probe 30 
would be expected to hybridize with its target sequence, but 
the mismatch probe would not hybridize (or would hybridize 
to a significantly lesser extent). Preferred mismatch probes 
contain a central mismatch. Thus, for example, where a 
probe is a twenty-mer, a corresponding mismatch probe will 35 
have the identical sequence except for a single base mis-
match (e.g., substituting a G, a C or a T for an A) at any of 
positions 6 through 14 (the central mismatch). 
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The comparison of the obtained expression profile and the 
one or more reference profiles may be performed using any 
convenient methodology, where a variety of methodologies 
are known to those of skill in the array art, e.g., by 
comparing digital images of the expression profiles, by 
comparing databases of expression data, etc. Patents 
describing ways of comparing expression profiles include, 
but are not limited to, U.S. Pat. Nos. 6,308,170 and 6,228, 
575, the disclosures of which are herein incorporated by 
reference. Methods of comparing expression profiles are 
also described above. Patent documents describing various 
methods or algorithms for obtaining gene expression profiles 
include, but are not limited to, US20030165952; 
US20110236903A1; US2011 0165566A1; 
US2011 0098195A1; US2011 007 6685A1; 
US20100167939A1; US20100112710A1; 
US20090233297 A1; US20090186348A1; 
US20080171323A1; the disclosures of each of which is 
hereby incorporated herein by reference. Other methods for 
analyzing microarray data are well-known in the art includ-
ing coupled two-way clustering analysis, clustering algo-
rithms (hierarchical clustering, self-organizing maps) and 
support vector machines. See, e.g., Eisen et a!., 95 PROC. 
NATL. ACAD. SCI. USA 14863-68 (1998); Ermolaeva eta!, 
20 NATURE GENET. 19-23 (1998); Tamayo et a!., 96 
PROC. NATL. ACAD. SCI. USA 2907-12 (1999); Getz et 
a!., 97 PROC. NATL. ACAD. SCI. USA 12079-84 (2000); 
Brown et a!., 97 PROC. NATL. ACAD. SCI. USA 262-67 
(2000); and Holter et a!., 97 PROC. NATL. ACAD. SCI. 
USA 8409-14 (2000). 
The comparison step results in information regarding how 
similar or dissimilar the obtained expression profile is to the 
one or more reference profiles, which similarity information 
is employed to determine the phenotype of the sample being 
assayed. For example, similarity with a positive control 
indicates that the assayed sample has a responsive pheno-
type similar to the responsive reference sample. Likewise, 
similarity with a negative control indicates that the assayed 
sample has a non-responsive phenotype to the non-respon-
sive reference sample. 
The level of expression of a biomarker (e.g., FKBP1a, 
FKBP1b, junctophilin 3, junctophilin 4, calmodulin 3, a 
functional fragment thereof, or a variant thereof) can be 
further compared to different reference expression levels. 
For example, a reference expression level can be a prede-
termined standard reference level of expression in order to 
evaluate if expression of a biomarker or biomarker set is 
informative and make an assessment for determining 
whether the patient tests positive or negative for AD or risk 
Mismatch probes thus provide a control for non-specific 
binding or cross hybridization to a nucleic acid in the sample 40 
other than the target to which the probe is directed. Mis-
match probes also indicate whether a hybridization is spe-
cific or not. For example, if the target is present the perfect 
match probes should be consistently brighter than the mis-
match probes. In addition, if all central mismatches are 45 
present, the mismatch probes can be used to detect a 
mutation. The difference in intensity between the perfect 
match and the mismatch probe (IBM)-I(MM)) provides a 
good measure of the concentration of the hybridized mate-
rial. 50 of developing AD. Additionally, determining the level of 
expression of a biomarker can be compared to an internal 
reference marker level of expression which is measured at 
the same time as the biomarker in order to make an assess-
ment for determining whether the patient tests positive or 
In certain embodiments, the obtained expression profile of 
a biological sample from a subject at risk of AD is compared 
to a single reference profile (e.g., that of an individual 
known not to have AD or that of a universal control sample 
obtained from healthy individuals) to obtain information 
regarding the phenotype (e.g., positive or negative test of 
early-stage AD) of the sample being assayed. In yet other 
embodiments, the obtained expression profile is compared to 
two or more different reference profiles (e.g., that of indi-
viduals known not to have AD or that of two or more 
universal control samples from healthy individuals) to 
obtain more in depth information regarding the phenotype of 
the assayed sample. For example, the obtained expression 
profile may be compared to a positive and negative reference 
profile to obtain confirmed information regarding whether 
the sample has the phenotype of interest (e.g., indications for 
early-stage AD or being at risk of developing AD). 
55 negative for AD or risk of developing AD. For example, 
expression of a distinct marker panel which is not comprised 
of biomarkers of the subject technology, but which is known 
to demonstrate a constant expression level can be assessed 
as an internal reference marker level, and the level of the 
60 biomarker expression is determined as compared to the 
reference. In an alternative example, expression of the 
selected biomarkers in a tissue sample which is a non-AD 
sample can be assessed as an internal reference marker level. 
The level of expression of a biomarker may be determined 
65 as having increased expression in certain aspects. The level 
of expression of a biomarker may be determined as having 
decreased expression in other aspects. The level of expres-
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sian may be determined as no informative change in expres-
sion as compared to a reference level. In still other aspects, 
the level of expression is determined against a pre-deter-
mined standard expression level as determined by the meth-
ods provided in, for example, W02012037378, which is 
hereby incorporated herein by reference. 
The subject technology also encompasses kits for detect-
ing the presence of target in a biological sample. For 
example, the kit can comprise a labeled compound or agent 
capable of detecting target protein or mRNA in a biological 10 
sample; means for determining the amount of target in the 
sample; and means for comparing the amount of target in the 
sample with a standard. The compound or agent can be 
packaged in a suitable container. The kit can further com-
prise instructions for using the kit to detect target protein or 15 
nucleic acid. 
2. Prognostic Assays 
The assays described herein, such as the preceding diag-
nostic assays, can be utilized to identify a subject having or 
at risk of developing AD, MCI or other cognitive impair- 20 
ments. Furthermore, the prognostic assays can be used to 
determine whether a subject can be administered an agent 
(e.g., an agonist, antagonist, peptidomimetic, protein, pep-
tide, nucleic acid, small molecule, or other drug candidate) 
to treat a disease or disorder associated with AD, MCI or 25 
other cognitive impairments. For example, such methods 
can be used to determine whether a subject can be effectively 
treated with an agent for a disorder such as AD or other 
cognitive impairments. Thus, the present subject technology 
provides methods for determining whether a subject can be 30 
effectively treated with an agent for a disorder associated 
with increased or decreased target expression or activity in 
which a test sample is obtained and target protein or nucleic 
acid expression or activity is detected (e.g., wherein the 
abundance of target protein or nucleic acid expression or 35 
activity is diagnostic for a subject that can be administered 
the agent to treat a disorder associated with increased or 
decreased target expression or activity). 
This subject technology is further illustrated by the fol-
lowing examples which should not be construed as limiting. 40 
The contents of all references, patents and published patent 
applications cited throughout this application, are incorpo-
rated herein by reference. 
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physiology or microarray analysis. Measures included levels 
of RNA associated with Ca2+ dyshomeostasis, quantification 
ofFkbplb, calcium channel and RyR2 protein levels, intra-
cellular measures of the post-burst AHP, accommodation 
and intracellular Ca2+ dynamics. control AAV (AAV titer, 
3.56E12 GC) or received no treatment. 
Three to 4 weeks after injection, intracellular recordings 
of the slow after hyperpolarization (sAHP) were obtained 
from CAl pyramidal neurons in acute hippocampal slices 
from both ipsilateral and contralateral sides of nine Fkbpl b-
injected animals. Subsequently, qPCR of Fkbplb was per-
formed on tissue from the dorsal tips and one slice each from 
both hippocampi of eight of the nine animals studied elec-
trophysiologically. In addition, brains of two other animals 
unilaterally injected in hippocampus with AAV bearing the 
Fkbplb were prepared for immunohistochemical studies. 
Microinjection protocol. Under isoflurane anesthesia, rats 
were placed in a David Kopf Instruments stereotaxic frame. 
Small holes were drilled in the skull either unilaterally or 
bilaterally (at points from bregma: posterior, 4.5 mm; lateral, 
3.0 mm), and the dura was pierced to allow for microinjec-
tion. A Hamilton micro syringe was lowered 1.6 mm into the 
dorsal hippocampus, a region critical for spatial memory. At 
the target injection site (CAl stratum oriens at the peak of 
the curve of stratum pyramidale), 2 fll of AAV-containing 
vehicle was delivered at a rate of0.2 fll/min using a Stoelting 
QSI microinjection pump. After injection, the syringe was 
left in place for 5 min, then the small holes in the skull were 
filled with bone wax, and the incision was sutured. Two to 
4 weeks after unilateral microinjections of AAV, rats were 
killed, and the brains prepared for sectioning and micros-
copy. See also, Gant eta!., 2011. 
qPCR. For mRNA quantification, one-step real-time 
reverse transcription (RT)-PCR was used. RT-PCR amplifi-
cation was performed as described previously (Chen eta!., 
2000) using an ABI prism 7700 sequence detection system 
(Applied Biosystems) and TaqMan One Step RT-PCR 
reagents (Applied Biosystems ). All samples were run in 
duplicate in a final volume of 50 fll containing 50-100 ng of 
cellular RNA and a Taq-Man probe (200 f.LM) and primers 
(300 nM each) with an amplicon spanning the rat Fkbplb 
eDNA region from nucleotides 155 to 259. Cycling param-
eters for all assays were as follows: 30 min at 48° C., 10 min 
at 95° C. followed by 40 cycles of 15 sat 95° C., and 1 min 
EXAMPLES 
Example 1 
AAV-mediated expression of the Fkbpl b open 
reading frame (ORF) can counteract Ca2 + 
dyshomeostasis and altered gene expression in the 
hippocampus of aging rats 
45 at 60° C. Primers were designed using Primer Express 
software (version 1.5; Applied Biosystems) and chemically 
synthesized by Applied Biosystems (forward primer, 
5'-GCAAGCAGGAAGTCATCAAAGG-3' SEQ ID N0.1; 
reverse primer, 5'-CAGTAGCTCCATATGCCACATCA-3' 
Methods and Materials 
Subjects. Studies on adult animals used 3- to 4-month-old 
male Fischer 344 rats obtained from Harlan. All protocols 
and procedures were performed in accordance with institu-
tional guidelines and were approved by the Animal Care and 
Use Committee. 
FKBPl b over expression in vivo with adena-associated 
virus vectors. To achieve selective expression in vivo, an 
adena-associated virus (AAV) vector was used to express 
Fkbplb mRNA in vivo. Aged (22 mo) F344 rats received 
unilateral or bilateral injections of 2 fll of AAV bearing the 
Fkbpl b construct at a rate of 0.2 fll/min. Following 2-3 
weeks of recovery the rats were sacrificed and tissue was 
utilized for qPCR, immunohistochemistry, slice electro-
50 SEQ ID N0.2; TaqMan probe, 5'-AGCTCATCTGGGCA-
GCGCCTTCTT-3' SEQ ID N0.3). The RNA levels of 
glyceraldehyde-3-phosphate dehydrogenase were used as 
normalization controls for RNA quantification. 
Patch-clamp recording ofCa2 + channel current in cultured 
55 neurons. Whole-cell recordings of pharmacologically iso-
lated Ca2 + channel currents, using Ba2 + as the charge carrier, 
were obtained from neurons in primary hippocampal cell 
cultures at 9-12 DW, as described previously (Porter eta!., 
1997; Blalock eta!., 1999; Breweret a!., 2001; Norris eta!., 
60 2002). electrophysiological data were acquired at 5-20 kHz 
using a patch-clamp amplifier (Axopatch 200A), DigiData 
1320 digital input/output board and pClamp 7 (Molecular 
Devices). Cell capacitance measures, membrane resistance, 
access resistance, and holding current were obtained from 
65 the membrane properties function in pClamp7. All cells 
were held at + 70 m V unless stated otherwise. Current-
voltage (I-V) relationships were determined by stepping the 
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voltage in increments of 10 m V from 70 to +60 m V for 150 
ms. Current was averaged over five traces for each mea-
surement point, and current density was determined by 
dividing current by cell membrane capacitance (picoam-
peres per picofarad). 
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response was determined by subtracting the post-ryanodine 
Ca2+ response from the pre-ryanodine response [(pre-ryano-
dine% llF/F)-(post-ryanodine% llF/F)=ryanodine sensitive 
component]. 
Current-clamp intracellular recording in hippocampal 
slice pyramidal neurons. Young-adult male F344 rats were 
anesthetized in a C02 chamber before rapid decapitation. 
Our sharp-electrode electrophysiological methods have been 
described previously (Thibault et a!., 2001; Gant et a!., 
2006). Briefly, intracellular recordings were obtained from 
CAl pyramidal neurons in hippocampal slices (350-+m-
thick) maintained in oxygenated ACSF (in mM: 128 NaCI, 
1.25 KH2P04, 10 glucose, 26 NaHC03, 3 KCI, 2 CaCI2, 
and 2 MgCI2), using sharp glass pipettes filled with HEPES 
(10 mM), KMeS04 (2M), and Calcium Orange tetrapotas-
sium salt (5 mM; Invitrogen). Electrophysiological data 
were acquired and analyzed using pC!amp 8, a sharp-
electrode amplifier (Axoclamp 2B), and a DigiData 1320 
board (Molecular Devices). Voltage records were digitized 
at 2-20kHz and low-pass-filtered at 1 kHz. Input resistance 
and AHP measures were obtained in current-clamp mode. 
AHP duration and sAHP amplitude were measured after four 
Na+ APs triggered by an intracellular depolarizing pulse. 
The 5 mM concentration of Ca2+ indicator used is in a range 
commonly used in slice imaging experiments (Jaffe et a!., 
1992; Brown and Jaffe, 1994; Jaffe and Brown, 1994) and 
apparently does not distort AHP waveforms or obscure aging 
differences in the AHP (Thibault et a!., 2001; Gant et a!., 
2006). 
Statistical analyses. Data analysis was performed with 
Clampfit8(Molecular Devices), and statistical analysis was 
performed with Stat-View (SAS Institute). Variables were 
analyzed using ANOVA across all groups with means and 
SEs reported. Fisher's protected least significant difference 
10 (PLSD) test was used for post hoc group comparisons. p 
values +0.05 were considered significant. 
This microinjection results in overexpression of FKBPl b 
mRNA and protein (confirmed by qPCR and immunohisto-
15 chemistry). The electrophysiological effects of unilateral 
microinjection into one hippocampus of aging rats of adena-
associated viral (AAV) vector containing the open reading 
frame (ORF) of the Fkbpl b gene is shown in FIG. 1. The 
quantitative group measures (mean+/-SEM) of intracellular 
20 electrode recordings of membrane voltage responses that are 
well-established to vary in magnitude with the amount of 
calcium released by intracellular ryanodine receptors (see 
Gant eta!, 2006). As shown in FIG. 1, the voltage responses 
obtained in this study are the amplitude of the calcium-
25 dependent medium afterhyperpolarization (mAHP)(top 
panel), amplitude of the calcium-dependent slow afterhy-
perpolarization (sAHP)(middle panel), and duration of the 
calcium-dependent slow afterhyperpolarization (sAHP) 
(bottom panel). The data reveal significant differences in 
Ca2 + imaging. Methods used were similar to those 
described previously by several groups (Miyakawa et a!., 
1992; Brown and Jaffe, 1994; Jaffe and Brown, 1994; Magee 
and Johnston, 1995; Thibault eta!., 2001; Gant eta!., 2006). 
Individual CAl neurons impaled with sharp pipettes and 
loaded with the Ca2+ indicator Calcium Orange were imaged 
30 these responses in neurons recorded from the viral vector-
injected hippocampus vs. those recorded from the control 
(non-injected) hippocampus, such that the injected-side neu-
rons exhibit a younger phenotype (lesser magnitude). Larger 
amplitude AHPs develop with aging and have been corre-
35 lated with impaired memory. 
on the stage of a Nikon E600 microscope equipped with a 40 
water immersion objective and a CCD camera (Roper Sci-
entific/Princeton Instruments). Calcium Orange was allowed 
These results show that the AAV microinjections impact 
several biotargets of aging rats, indicating that calcium 
release-stabilizing molecules such as FKBPs are novel 
therapeutic agents and/or targets for interventions aimed at 
40 protection against unhealthy brain aging or Alzheimer's 
disease. 
to diffuse into the cell for at least 10 min before Ca2+ 
fluorescence measures were performed. Calcium Orange 
was excited using a wavelength switcher (Sutter Instruments 
Lambda DG-4) and software control (Axon Imaging Work-
bench; version 2.2.1.54; Molecular Devices). The 575 nm 
wavelength was monitored through a dichroic mirror cen- 45 
tered at 570 nm during excitation with the 550 nm wave-
length. The intracellular Ca2 + response was elicited by 10 s 
of 7 Hz repetitive synaptic stimulation (RSS) delivered to 
the Schaffer collaterals via bipolar stimulation electrode. 
Stimulation intensity was set at AP threshold and generated 50 
an action potential on essentially each pulse (Thibault et a!., 
2001 ). Ca2+ responses were measured in a region of interest 
corresponding to the visible outline of the cell soma, exclud-
ing surrounding low-intensity diffracted light. Although the 
central region of the neuron appears brighter (see FIG. 6, 55 
inset), this may be related in part to greater indicator loading 
in this thicker central region of the cell (Tsien, 1988; 
Nicotera et a!., 1994 ). After background subtraction from an 
area devoid of cells adjacent to the recorded cell, percentage 
change in fluorescence was determined relative to baseline 60 
(% F/F). Optical sampling rate averaged +5 Hz, which 
appeared sufficiently sensitive to detect significant changes 
in the Ca2 + response. Excitation of Calcium Orange was 
essentially continuous during a 10 strain ofRSS, but control 
runs showed that bleaching was minimal ( +0.21 +0.09% at 5 65 
s RSS; +0.69+0.35% at 10 s RSS; n+ 7 cells). The ryanodine-
sensitive component (CICR component) of the Ca2+ 
Example 2 
FKBPlb Overexpression and Reversal of Aging 
Biomarkers 
The aim of this study was to determine whether AAV-
mediated overexpression of the Fkbp 1 b open reading frame 
(ORF) can reverse hippocampal Ca2 + dyshomeostasis and 
cognitive impairment in aging rats. Aged (22 mo) F344 rats 
received unilateral or bilateral injections of 2 fll of AAV 
bearing the Fkbplb ORF construct or empty AAV vector 
control. IHC and qPCR analyses revealed substantial 
upregulated FKBPl b in hippocampal sites of AAV-ORF 
injection. See FIG. 3. 
Following 4-5 weeks, the rats were tested on a spatial 
water maze, after which hippocampal tissue was utilized for 
slice electrophysiology, and qPCR, immunohistochemistry 
or microarray analysis. Results showed that the AAV-ORF 
microinjections reversed electrophysiological and behav-
ioral biomarkers of aging in rats. More importantly, it was 
determined that overexpression of FKBPl b in hippocampus 
of aged rats improved memory and maze learning. See FIG. 
4. These results show that calcium release-stabilizing mol-
ecules such as FKBPs can be used as therapeutic agents for 
treatment of age-related cognitive malfunctions. 
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Those skilled in the art will recognize, or be able to 
ascertain using no more than routine experimentation, many 
equivalents to the specific embodiments of the subject 
technology described herein. Such equivalents are intended 
to be encompassed by the following claims. The results 
indicate that 
<160> NUMBER OF SEQ ID NOS, 3 
<210> SEQ ID NO 1 
<211> LENGTH, 22 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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of other forms without departing from the spirit thereof. The 
accompanying claims and their equivalents are intended to 
cover such forms or modifications as would fall within the 
scope and spirit of the subject technology. The contents of all 
references, patents and published patent applications cited 
throughout this application, are incorporated herein by ref-
erence. 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 1 
gcaagcagga agtcatcaaa gg 
<210> SEQ ID NO 2 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
22 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 2 
cagtagctcc atatgccaca tea 
<210> SEQ ID NO 3 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
23 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
probe 
<400> SEQUENCE, 3 
agctcatctg ggcagcgcct tctt 
The foregoing description is provided to enable a person 45 
skilled in the art to practice the various embodiments 
described herein. While the subject technology has been 
particularly described with reference to the various figures 
and configurations, it should be understood that these are for 
50 illustration purposes only and should not be taken as limiting 
the scope of the subject technology. 
Furthermore, to the extent that the term "include," "have," 
or the like is used in the description or the claims, such term 
is intended to be inclusive in a manner similar to the term 55 
"comprise" as "comprise" is interpreted when employed as 
a transitional word in a claim. 
The word "exemplary" is used herein to mean "serving as 
an example, instance, or illustration." Any embodiment 
described herein as "exemplary" is not necessarily to be 60 
construed as preferred or advantageous over other embodi-
ments. 
While certain aspects and embodiments of the subject 
technology have been described, these have been presented 
by way of example only, and are not intended to limit the 65 
scope of the subject technology. Indeed, the novel methods 
and systems described herein may be embodied in a variety 
24 
What is claimed is: 
1. A method of treating Alzheimer's Disease (AD), early-
stage AD, mild cognitive impairment (MCI), or other forms 
of age-related cognitive decline in a subject in need thereof, 
comprising administering to the subject by way of injection 
or infusion into brain tissue that is affected by AD, early-
stage AD, MCI or age-related cognitive decline, a replica-
tion-defective viral expression vector comprising a poly-
nucleotide sequence that encodes at least one ofFKBPla or 
FKBPlb, or a polynucleotide having at least about 60% 
sequence identity over its entire length to at least one of 
FKBPla, FKBPl b, or both and encoding a polypeptide 
having calcium release inhibiting activity on ryanodine 
receptors (RyRs ), said polynucleotide sequence being oper-
ably linked to a promoter sequence, wherein expression of 
the at least one of FKBPla or FKBPl b, or the polynucle-
otide having at least about 60% sequence identity over its 
entire length to at least one of FKBPla, FKBPlb, or both, 
in the brain tissue of the subject results in reduced calcium-
release from RyRs in the brain tissue of the subject and 
reduces cognitive impairment of the subject. 
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2. The method of claim 1, wherein the replication-defec-
tive viral expression vector is an adena-associated expres-
sion vector. 
3. The method of claim 1, wherein the replication-defec-
tive viral expression vector comprises a polynucleotide 
encoding FKBPl b. 
4. The method of claim 1 wherein the polynucleotide 
encodes FKBPla. 
5. The method of claim 2 wherein the replication-defec-
tive viral expression vector is injected or infused into the 10 
hippocampus of the subject. 
6. A method of treating Alzheimer's Disease (AD), early-
stage AD, mild cognitive impairment (MCI), or other forms 
of age-related cognitive decline in a subject in need thereof, 
comprising administering to the subject by way of injection 15 
or infusion into brain tissue that is affected by AD, early-
stage AD, MCI or age-related cognitive decline, a replica-
tion-defective viral expression vector comprising a poly-
nucleotide sequence that encodes at least one of FKBPla or 
48 
FKBPlb, said polynucleotide sequence being operably 
linked to a promoter sequence, wherein expression of the 
FKBPla, FKBPl b , or both in the brain tissue of the subject 
results in reduced calcium-release from ryanodine receptors 
in the brain tissue of the subject and reduces cognitive 
impairment of the subject. 
7. The method of claim 6, wherein the replication-defec-
tive viral expression vector is an adena-associated expres-
sion vector. 
8. The method of claim 6, wherein the replication-defec-
tive viral expression vector comprises a polynucleotide 
encoding FKBPl b. 
9. The method of claim 6 wherein the polynucleotide 
encodes FKBPla. 
10. The method of claim 6 wherein the replication-
defective viral expression vector is injected or infused into 
the hippocampus of the subject. 
* * * * * 
